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The work that we are presenting comes from a collaboration bet-
ween the Bioengineering group of the University of Padova and
the Section of Neuroadaptation and Protein Metabolism (SNPM).
SNPM is an integral part of the Neuroscience Research com-
munity at the National Institutes of Health (NIH), the primary
United States Federal agency for conducting and supporting me-
dical research. SNPM laboratories are located on the NIH cam-
pus in Bethesda, Maryland in the Division of Intramural Re-
search of the National Institute of Mental Health (NIMH).
The aim of SNPM research is to understand the role of protein
metabolism in adaptive responses of the nervous system and to
do it they develop, apply, and refine imaging methods that can
be used to quantitatively measure these changes in vivo in all
structures of the nervous system in animals and in man.
The role of the Bioengineering group of Padova University in
this collaboration is to provide ideas to develop and improve these




Figure 1: The pictures show the NIH and its scientists at work. NIH is
an agency of the U.S. Department of Health and Human Services. With
the headquarters in Bethesda, Maryland, the NIH has more than 18,000
employees on the main campus and at satellite sites across the United States.
Helping to lead the way toward important medical discoveries that improve
people’s health and save lives, NIH scientists investigate ways to prevent
disease as well as the causes, treatments, and even cures for common and
rare diseases. Composed of 27 Institutes and Centers, the NIH provides
leadership and financial support to researchers in every state and throughout
the world.
The NIH annually invests over $28 billion in medical research. More than
83% of the NIH’s funding is awarded through almost 50, 000 competitive
grants to more than 325, 000 researchers at over 3, 000 universities, medical
schools, and other research institutions in every state and around the world.
About 10% of the NIH’s budget supports projects conducted by nearly 6,000
scientists in its own laboratories (www.nih.gov).
Chapter 1
Introduction
The Biosynthesis of proteins is a fundamental process for the
physiological maintenance and functioning of organisms. In fact,
it is through the action of the different proteins that every bio-
logical system can achieve and control all metabolic processes
required for life. The event of the synthesis, even though it fol-
lows a well-defined process common to each cell of the organism,
assumes different facets depending on the particular biological
system to which it refers. For example in the central nervous
system (CNS), de novo protein synthesis is critical for adaptive
responses such as long-term memory formation. Animal studies
indicate, in fact, that regional rates of cerebral protein synthesis
(rCPS) are altered in models of various clinical disorders and in
certain physiologic states. It has been shown that rCPS is mod-
ified during brain development and during the process of aging
and it is directly correlated to many of the diseases of the CNS.
With the development and validation of the L-[1 −11 C]leucine
PET method ([28]; [30]), fully quantitative measurement of rCPS
in vivo in human subjects is now possible. The method has
been implemented in awake, healthy young men and the results
demonstrated that reproducible measurements of rCPS with low
variability can be obtained [2]. Recently, the method has been
utilized in study of normal human brain in awake and under
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anesthesia [3]. Future applications are expected in subjects with
neurodegenerative diseases, and with neurodevelopmental disor-
ders.
The analysis of L-[1−11C]leucine PET data in non-human pri-
mates [30] and in human subjects ([34]; [2]; [3]) is focused in
particular to the region-of-interest (ROI) level. This is due to
two reasons: firstly the ROI data are averaged over large num-
bers of voxels in the field of view of the PET scanner, and so
noise is reduced. Secondly, the computational burden of ana-
lyzing data at the voxel level can be extraordinarily high. Even
though the elaboration at ROI level has a lot of advantages, it
also represents an important limitation for the homogenous tis-
sue kinetic model (HOM) that the method uses for the rCPS
quantification. In fact, due to the limited spatial resolution of
PET, a region of interest (ROI) likely contains a heterogeneous
mixture of tissues, a characteristic that the HOM does not take
into account in its representation of the system. A different
approach to the problem can be done through Spectral Analy-
sis (SA) [8]. This technique applies to heterogeneous as well
as homogeneous tissues, and therefore, it might be an alterna-
tive quantitative method. In the present work we found that the
standard SA algorithms ([8]; [36]) cannot be directly applied to
the L-[1−11 C]leucine PET data because the estimates that they
provide for rCPS at the ROI level are not physiological and in are
not in agreement with the previous studies ([2]; [35]). For this
reason we developed a new algorithm based on SA to estimate
rCPS and the other variables of interest at the ROI level. The
method was tested in simulation experiments and then applied
to measured data. The results were compared to the estimates
provided by the alternative approaches for rCPS quantification
from the L-[1−11 C]leucine PET data.
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Chapter 2
The Biosynthesis of Protein
2.1 The regional rate of cerebral protein syn-
thesis
2.1.1 The importance of protein synthesis
Biosynthesis of proteins is a fundamental process necessary for
the physiological maintenance and functioning of organisms. In
the central nervous system (CNS), de novo protein synthesis is
critical for adaptive responses such as long-term memory forma-
tion.
Animal studies indicate that the protein synthesis is altered
in models of various clinical conditions including fragile X syn-
drome1 [25], Phenylketonuria2 [29], ischemia/stroke [40], CNS
tumors [39], epilepsy [7], and in certain physiologic states such
as slow wave sleep [22]. Studies in rodents have demonstrated
that de novo protein synthesis changes during the process of ag-
1Fragile X syndrome (FrX) is the most common inherited form of mental retardation in
males with an estimated frequency of 1/4000. It is caused by the absence of the fragile X
mental retardation protein (FMRP) encoded by the silenced fragile X mental retardation
gene (Fmr1).
2Phenylketonuria (PKU) is an autosomal recessive genetic disorder characterized by a
deficiency in the enzyme phenylalanine hydroxylase (PAH). This enzyme is necessary to
metabolize the amino acid phenylalanine to the amino acid tyrosine. This condition can
cause problems with brain development, leading to progressive mental retardation and
seizures.
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ing [16] and during brain development [33]. Activity-dependent
protein synthesis is thought to be an integral step in many forms
of synaptic plasticity [23]. This fact is confirmed in a study
about the developmental plasticity in monkeys where region-
ally selective changes in protein synthesis were found. For all
these reasons, a measure of the regional rate of cerebral protein
synthesis (rCPS) would have many applications in the study
of normal human brain and in clinical medicine by providing a
new tool to investigate disorders of brain development, recovery
from brain injury, and neurodegenerative diseases. In particu-
lar, variations in rCPS likely reflect adaptive processes taking
place over a longer period of time compared with the acute phys-
iological changes signaled by measurements of regional cerebral
metabolic rate for glucose or cerebral blood flow. Thus, changes
in rCPS are expected to reflect long-term adaptive phenomena
and provide complementary information to existing techniques
on elucidating CNS processes.
2.1.2 A PET technique for the measurement of rCPS
One of the most informative ways to study the protein synthe-
sis is through functional imaging. Functional imaging meth-
ods have been developed, refined and finally applied to quan-
titatively measure the specific metabolism processes in vivo in
all structures of the nervous system in animals and in man.
Through them maps of the absolute rates of physiological or bio-
chemical processes simultaneously can be provided in all parts of
the body of the living organism, but for the particular purposes
of this work, we will focus to those techniques that investigate
the human brain.
There are different types of functional brain imaging meth-
ods, such as the quantitative autoradiography, the functional
magnetic resonance imaging (fMRI), the laser Doppler flowme-
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Figure 2.1: A representation of the complex mechanisms of the protein syn-
thesis process (www.stemcells.nih.gov)
try or positron emission tomography (PET). PET is a nuclear
medicine imaging technique which produces a three-dimensional
image or map of functional processes in the body. The sys-
tem of measure detects pairs of gamma rays emitted indirectly
by a positron-emitting radionuclide, which is introduced into
the body on a biologically active molecule (tracer). From the
spatial-temporal registration of the tracer it is possible to quan-
tify the physiological process associated in a specific location of
the examined subject trough a computer analysis. The type of
metabolic parameters that PET provides, depends on the type
of tracer used during the PET study and on the mathematical
method of data elaboration. Actually different kind of tracers
and quantification methods exist, and this allows PET to be ap-
plied in different areas of medical care like oncology, cardiology,
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psychiatry and neurology. In this work we also utilize a PET
approach to measure our protein synthesis parameters of inter-
est. In fact, even though different techniques to estimate the
regional rate of protein synthesis had been developed, only the
L-[1−11C]leucine PET method ([28]; [30]; [2]) allows to quantify
it in human in vivo.
In this method the L-[1 −11 C]leucine3 is injected in the pa-
tient with a intravenous access. The radioactivity of the tracer
in brain is then registered from the PET instrumentation. Af-
ter this process the data are elaborated using a mathematical
estimation algorithm that finally provides the quantification of
the variables of interest. For the correctness of the results the
role of the leucine is essential. Before the L-[1 −11 C]leucine
PET method, studies with others radiolabeled amino acid trac-
ers were tried to measure rCPS but none of them provided
quantitative results ([26]; [14]) as a consequence of the amino
acid’s recycling effects that the methods don’t consider, unlike
the leucine technique. If plasma is the only source of the amino
acid in the tissue, the integrated specific activity of the precur-
sor amino acid in the tissue can be estimated from the measured
time course of the amino acid in arterial plasma and a compart-
mental model of the behavior of the amino acid in the tissue,
but, it has been shown that, in brain, protein degradation in the
tissue is also a significant source of amino acid ([31]; [29]). Even
60 minutes after a bolus injection of a radiolabeled amino acid,
the sizeable pool of tissue protein is largely unlabeled and amino
acids derived from the steady-state breakdown of unlabeled pro-
tein are constantly diluting the specific activity of the precur-
sor amino acid coming from plasma. Studies in experimental
animals have shown that this can result in a significant under-
3Leucine is an amino acid, normally involved in the human metabolism. By a chemical
reaction one of the carbon atoms is substituted with 11C and the L-[1−11 C]leucine is so
produced. In this way we obtained a PET tracer that allows following the process involved
in the leucine metabolism and so also the protein synthesis.
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estimation of rCPS [31]. The L-[1 −11 C]leucine PET method
accounted for the effect of recycling for measurement of rCPS
by including in the operational equation a factor, λ, which is the
fraction of the precursor pool for protein synthesis derived from
arterial plasma. The fraction derived from tissue proteolysis is
then 1-λ [28]. Because the L-[1 −11 C]leucine method accounts
for the unlabeled leucine which is recycled from proteolysis, it
provides a truly quantitative rate of protein synthesis. The L-
[1−11 C]leucine PET method has been validated in non-human
primates [30] and applied to humans [34]. The reproducibility
and variability of measurements of λ and rCPS have been stud-
ied in normal subjects [2]. Recently studies have compared the
differences of λ and rCPS in awake and propofol4 anesthetized
normal subjects. In the next sections we present the details of
the L-[1 −11 C]leucine PET method. To be clearer we distin-
guish two parts: the first one, which explains the whole process
for data acquisition from the patients, and the second that is
directly related to the quantification of λ and rCPS from the
acquired data.
4Propofol is a short-acting intravenous sedative agent used for the induction of general
anesthesia for adults and children, maintenance of general anesthesia, and sedation in
medical contexts, such as intensive care unit (ICU) sedation for intubated, mechanically
ventilated adults, and in procedures such as colonoscopy.
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2.2 The acquisition of the data
In this section we present the whole process to obtain the data
used for the quantification of metabolic parameters, from the
choice of the subjects to the acquisition and elaboration of the
PET images.
The data from the human subjects that we used in this work to
evaluate the regional rate of cerebral protein synthesis were col-
lected with a well-defined acquisition program [2]. This sched-
ule, in fact, has to be very rigid to ensure the patient safety
and certify the validity of the data obtained. The scheme of
acquisition can be split in the following steps:
• The choice of the subjects
• The Brain MRI
• The L-[1−11 C]leucine synthesis
• The PET studies
• The L-[1−11 C]leucine blood sample analysis
• The PET data time courses
2.2.1 The choice of Subjects
Eighteen to 24 year old male volunteers were prospectively eval-
uated by clinical history, physical examination and a structured
clinical interview which is designed to identify psychiatric diag-
noses based on DSM-IV criteria [38]. The criteria to be suitable
for the study were:
1. no current or past diagnoses of psychiatric, neurologic or
chronic medical condition;
2. no history of neurologic trauma;
8
3. no family history of genetically transmissible neurologic
syndrome;
4. HIV negative.
Subjects were excluded if they did not meet all inclusion cri-
teria. Nine right handed subjects, in a range of 21-24 years
old, were selected for the study. Each subject underwent two
L-[1−11C]leucine PET examinations and one non-contrast mag-
netic resonance scan (MRI) of the brain. The repetition of two
PET studies was used to study the repeatability of the method
[2] but for this work only the data acquired with the first exam-
ination has been used. The protocol was approved by the Na-
tional Institutes of Health Combined Neuroscience Institutional
Review Board and the National Institutes of Health Radiation
Safety Committee. All subjects gave written informed consent
prior to study enrollment.
2.2.2 Brain MRI
All subjects underwent a non-contrast T1 weighted MRI of the
brain for region of interest (ROI) placement and to exclude
structural brain abnormalities. MRI examinations were per-
formed using a head coil on either a 1.5 Tesla Signa (GE Medi-
cal Systems, Milwaukee, WI), or a 3 Tesla unit (Phillips). Typ-
ical imaging parameters were: 3D fast spin gradient echo, echo
time/repetition time: 9 ms/2 ms, 20 flip angle, 1 net excita-
tion, in plane field of view (FOV): 240 mm, 256 x 256 matrix,
1 mm slice thickness without interleaved slices. Images were re-
constructed to voxel dimensions of 0.94 x 0.94 x 1 to 1.3 mm,
and interpolated to voxel dimensions of 0.94 mm3. ROIs were
placed on each MRI by visually identifying anatomic landmarks,
and manually outlining the individual regions and whole brain.
For some subjects some regions, in particular for the smallest
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like the hypothalamus, a correct anatomical identification was
impossible to do and so we avoided inclusion of this data in the
quantification process.
2.2.3 L-[1−11 C]Leucine Synthesis
D,L-[1−11C]Leucine was prepared from H11CN with a modified
Strecker-Bucherer reaction [32]. Pure L-amino-acid was isolated
from the racemic mixture by chiral HPLC with a Chirobiotic
T column (10 x 250 mm) (Advanced Separation Technologies
Inc., Whippany, NJ, USA), mobile phase of ethanol/water: 5/95
(V/V), and a flow rate of 3 ml/min. Retention times of the L-
and D-isomers were approximately 7 and 8 min as determined
by the corresponding standards. L-[1−11C]leucine was obtained
with a radiochemical purity of >99% and an estimated specific
activity of 3 mCi/nmol.
2.2.4 PET Studies
Subjects were instructed to consume a high protein snack and
then fast for eight hours prior to each PET study. On the morn-
ing of the study, arterial and intravenous lines were placed in
the radial artery of the non-dominant hand and contralateral
antecubital fossa, respectively. PET studies were performed on
very high-performance PET instrumentation whose particular-
ities will be examined in detail in the next section. Subjects
were positioned in the scanner and a 3 min transmission scan
was acquired for optimal subject positioning within the field of
view (FOV). A 6 minute transmission scan was then obtained for
attenuation correction. Ninety-minute dynamic emission scans
were initiated coincident with the intravenous infusion of 20-30
mCi of L-[1 −11 C]leucine administered over 2 minutes. Data
were acquired in list mode and reconstructed using the motion-
compensated 3D ordinary Poisson ordered subset expectation
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maximum (OSEM) algorithm. 3D frames of data were recon-
structed to 207 slices 1.23 mm thick. Each image was organized
as 42 frames of data with the following time grid: 16 x 15 sec, 4
x 30 sec, 4 x 60 sec, 4 x 150 sec, 14 x 300 sec. With this sched-
ule data were sampled frequently at the beginning of experiment
when the tracer activity was changing rapidly and less frequently
when the activity was changing more slowly. All activities were
decay corrected to the time of radiotracer injection.
2.2.5 [11C]Leucine Blood Sample Analysis
Arterial blood sampling was initiated concurrently with the start
of the 11Cleucine infusion to determine the time courses of the
concentrations of unlabeled and labeled leucine in plasma and
total 11C and 11CO2 activities in whole blood. Timed samples
were hand drawn continuously (∼ one sample/9-10 sec) for the
first 4 minutes, and at increasing intervals thereafter for a total
of ∼ 40 samples per study. The procedure apportioned blood
samples as follows:
1. Approximately 0.2-0.3 mL of whole blood was transferred
to a preweighed tube containing 1 N NaOH; the tube was
immediately reweighed and counted in a gamma counter
(Cobra II Auto Gamma, Packard Instrument CO., Inc.,
Downers Grove, IL, USA) to obtain total activity in whole
blood.
2. Approximately 0.5 mL was centrifuged to remove red cells
and 0.2 mL of plasma from each sample was diluted in dis-
tilled water and deproteinized at 4◦C by the addition of
a solution of 16% (W/V) sulfosalicylic acid containing L-
norleucine (0.04 mmol/L) as an internal standard for amino
acid analysis. Labeled and unlabeled leucine concentra-
tions in the acid-soluble fraction were assayed by gamma
11
counting and fluorescence detection of post-column ortho-
phthaldehyde derivatized amino acids separated with ion
exchange HPLC (Agilent Technologies, Inc., Santa Clara,
CA, USA and Pickering Laboratories Equipment, Moun-
tain View, CA, USA), respectively.
3. Approximately 1 mL of whole blood was injected through
the septum of a sealed vial into 2 ml of 8% sulfosalacylic
acid. Attached to the septum of the vial was a polyethylene
cup with a filter paper soaked with 1 N NaOH. The vial
was weighed and, after allowing 30 min for the evolution of
11CO2, the filter paper was removed and counted.
11C activities in all samples were decay corrected to the time of
injection.
2.2.6 PET Data time courses
For each study, a 3D volume was constructed from the average of
the emission data acquired between 30 and 60 min. This volume
was isotropically smoothed with a Gaussian filter (FWHM 3
mm) and aligned to the MRI volume by use of the Flexible
Image Registration Toolbox (FLIRT) [12] with a 3D rigid body
transformation. The resliced average 30-60 min PET image was
visually reviewed for correct alignment with the MRI by use
of Vinci software (Volume Imaging in Neurological Research,
Co-Registration and ROIs Included, Max-Planck-Institute for
Neurological Research, Cologne, Germany). The transformation
parameters were then applied to each frame of the PET study
(without prior smoothing) to effect their alignment with the
MRI volume. ROIs drawn on MRIs were transferred to L-[1−11
C]leucine scans to compute regional tissue time-activity curves
(TACs).
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2.3 The PET instrumentation
The PET instrumentation, used to acquire the data of this work,
consists of a high technological system projected for researcher
studies. The system is particular for two reasons:
• It uses a new generation brain PET tomograph
• It utilizes a new high performance method for the recon-
struction of the images and their resolution recovery
In this section we present the features of this instrumentation to
understand the characteristics of the images provided by it.
2.3.1 The brain PET tomograph: the ECAT HRRT
The ECAT HRRT (High Resolution Research Tomograph) ([41];
[10]) is a dedicated brain and small animal PET scanner, with
design features that enable high image spatial resolution com-
bined with high sensitivity. The HRRT is the first commer-
cially available scanner that utilizes a double layer of LSO/LYSO
(lutetium-oxy-orthosilicate) crystals to achieve photon detection
with depth-of-interaction information. This technology allows a
reduction in crystal size and its short scintillation rise and decay
time a short coincidence time window with a reduction of dead
time.
The HRRT is built of eight panel detector heads arranged in
an octagon with a head to head distance of 46.9 cm for opposing
heads and 1.7 cm for neighboring heads. The gantry has a 35
cm diameter patient opening with an axially 25.2 cm long and
transaxially 31.2 cm wide electronic FOV (Field of View). The
HRRT is a Siemens PET scanner unique in its genre. In fact, if
we compare it with the GE Advance5 PET scanner (Figure 2.3)
5GE Advance PET scanner is the highest resolution PET system manufactured by GE
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Figure 2.2: Front view of the ECAT HRRT scanner by CPS Innovations,
Knoxville, TN. The topology of the HRRT is an octagon of dual-layer
(LSO/LYSO) detector banks, each bank being an array of 9 x 13 blocks,
and each block containing 8 x 8 crystals of size 2.1 x 2.1 x 10-mm each.
With 119,808 crystals, the HRRT has 4.5 billion potential lines of response.
The HRRT has a 35-cm patient port, making it suitable for human brain
studies as well as large animal studies.
it is evident that the performance of the HRRT is better. HRRT
has a smaller detection hole than the GE but it is at the same
time sensitive at a huge number of Line of Response (LOR) per
second. However, what is interesting for our data is the very
high resolution that HRRT has. This resolution contributes to
providing high quality brain images in which the volume of each
voxel is very small. To understand better in what this difference
of resolution consists we reported in Figure 2.4 the phantom
scans in the two different tomographs. In the HRRT image,
Medical Systems. Unlike the HRRT it is characterized by a FOV sufficiently large to study
not only the brain but all the human body.
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Figure 2.3: Comparison between GE Advance PET scanner and HRRT
we can see easily details of the phantom that are not present
in GE one. But it is not only high-quality of the scanner to
cause this difference. In fact, to arrive at these results, it is
necessary to correct the data from all the errors that affect the
acquisition protocol, like random coincidences and motion, and
only after this the images can be reconstructed. For this reason,
a very complete system to perform HRRT PET reconstruction
has been developed and optimized.
Figure 2.4: The different resolution between GE Advance PET scanner and
HRRT in a phantom scan [10].
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2.3.2 MOLAR: The Reconstruction Algorithm
The Motion-compensation OSEM6 [11] List-mode Algorithm for
Resolution-recovery Reconstruction (MOLAR) is a complete sys-
tem for managing and performing iterative PET reconstructions.
The system is the result of an ongoing collaboration between
three organizations in the NIH Intramural Research Program as
well as Yale University, SUNY Buffalo, and CPS Innovations,
Knoxville, TN, USA. MOLAR has been designed for use with
the ECAT HRRT (High Resolution Research Tomograph, CPS
Innovations) operating in list-mode but this reconstruction en-
gine is readily adaptable to any PET scanner. This system elab-
orates all the data acquired by PET scanner including the at-
tenuation correction coefficient, randoms estimate, scatter esti-
mate, number of events, crystal indices, motion-corrected event
coordinates and region-of-support bound. The motion correc-
tion information is tracked and elaborated via the Polaris Opti-
cal Tracking System (Northern Digital Inc., Waterloo, Ontario,
Canada). The system is very complex and requires a powerful
computational engine for the information processing. This is
made by a computer cluster of 46-nodes, each one with a double
AMD processor. The typical reconstruction time for one frame
is less than one hour. The MOLAR system applied to the HRRT
provides images with resolution of less than 3 mm and data are
corrected for attenuation, scatter and randoms. This character-
istic influences in a positive way the quality of the time-activity
curves associated with each voxel and so also the finally results
of the quantification.
6Ordered Subsets Expectation Maximization reconstruction algorithm.
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Figure 2.5: The MOLAR is not simply an algorithm but is a complex system






3.1 The kinetic model
After the acquisition and reconstruction of the L-[1−11C]leucine
PET data, the acquired information is processed for the quantifi-
cation of λ and rCPS. To do this, we identify the constants of a
kinetic model from which the variables of interest are calculated.
The features of this kinetic model and its capacity to describe
the physiological leucine system are crucial for the goodness of
the final results and for this importance we are going to present
in this section its main characteristics.
3.1.1 The kinetic model of unlabeled leucine
To define the kinetic model for the L-[1−11C]leucine PET data
it is necessary to analyze before the biochemical metabolism
associated with unlabeled leucine. From the knowledge of the
leucine metabolic system a comprehensive model of it can be
represented in Figure 3.1 [31]. In this model Cp, Ce and Cm rep-
resent the concentration of free leucine in plasma, extracellular
space and intracellular space respectively. Cpp and P represent
the leucine in t-RNA complex and in cellular protein. The rate
constants of the model are:
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Figure 3.1: The unlabeled leucine kinetic model
• K1, for carrier-mediated transport of leucine from plasma
to tissue;
• k2, for transport back from tissue to plasma;
• k3, for catabolism of leucine;
• k4, for leucine incorporation into protein;
• k5, for release of free leucine by protein degradation;
• k6, for deacylation of leucyl-tRNA;
• k7, for transfer of leucine from the intracellular leucine pool
to precursor;
• k8, for transport of leucine from extracellular space to in-
tracellular leucine pool;
• k9, for transport of leucine from intracellular pool to extra-
cellular space;
• k10, for transport of leucine from extracellular space to in-
tracellular pool for the protein synthesis.
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It is clearly evident that this model can not be used directly for
any estimation because it contains too many parameters, but
it provides a complete description of the leucine distribution
in the various brain compartments and their connections. For
these reasons, this model can be very useful as starting point to
define a model for L-[1−11C]leucine from which the parameters
can be estimated.
3.1.2 The Homogenous Kinetic Model for L-[1 −11 C]-
leucine
The model for the behavior of L-[1−11C]leucine in brain (Figure
3.2) was semplified from the comprehensive model for leucine
(Figure 3.1) [28]. It contains only four rate constants: K1
and k2 for carrier mediated transport from plasma to brain and
back from brain to plasma, respectively; k3 for metabolism of
leucine to yield CO2; and k4 for incorporation of leucine into
protein. The rate constants are identical for labeled and unla-
beled leucine. To obtain this result the following assumptions
are applied:
• The tissue region is homogenous with respect to concen-
trations of amino acids, rates of blood flow, and rates of
transport, metabolism, and incorporation of amino acids
into protein;
• The concentration of unlabeled leucine in arterial plasma
and rates of amino-acid metabolism and protein synthe-
sis are assumed constant during all the experiment period
(steady state);
• Concentrations of labeled leucine are sufficiently small that
the tracer theory holds, and there are no isotope effects
associated with its use;
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Figure 3.2: The L-[1 −11 C]leucine homogenous kinetic model (HOM) and
the simplified model for the unlabelled leucine.
• The model does not distinguish intra and extracellular spaces,
and pools of free leucine and tRNA-bound leucine are com-
bined and represented by a single tissue pool;
• There is no significant loss of label and no recycling or L-
[1−11 C]leucine from breakdown of labeled protein.
This last hypothesis can be justified, in light of the long av-
erage half-life (>3 days) of brain protein [17] compared to the
experimental time (90 minutes). For this reason, we know that
the rate constant for breakdown of unlabeled tissue protein, k5,
is very small. In the case of unlabeled protein, k5 acts on the
large pool of brain protein producing a significant amount of
unlabeled leucine in the tissue. In the case of labeled protein
k5 acts on the very small pool of labeled protein (P
∗) produced
during the study duration. We assume, therefore, that k5P
∗ ∼ 0.
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The total concentration of 11C in the field of view of the PET
camera (C∗T ) at time T includes free [
11C]leucine and [11C]leucine
incorporated into protein in the tissue (C∗E and P
∗, respectively)
as well as activity in the blood in the brain (VbC
∗
b , where Vb is the
fraction of the volume occupied by blood and C∗b is the concen-
tration of activity in whole blood). It also includes the labeled
products of [11C]leucine metabolism: 11CO2, and products of
11CO2 fixation. We assume negligible fixation of
11CO2 during
the experimental period [5], and that diffusible 11CO2 in brain
rapidly equilibrates with the arterial blood [5], i.e., its concen-
tration can be approximated by VDC
∗




activity in whole blood and VD is the brain/blood equilibrium
distribution volume of 11CO2. Therefore
C∗T (t) ' (1− Vb)[C∗E(t) + P ∗(t) + VDC∗c (t)] + VbC∗b (t). (3.1)
Time courses of C∗c , C
∗
b , and plasma
11leucine concentration (C∗p)
are measured from arterial blood samples taken at the time of
the PET study. For any set of rate constants, the time courses of
C∗E and P
∗ can be calculated from C∗p by solving the differential
equations corresponding to the compartmental model:{ dC∗E
dt = K1C
∗






In the model of Figure 3.2 also the behavior of the unlabeled
leucine is described. The compartmental model defined the fol-
lowing equations{
dCE
dt = K1Cp(t)− (k2 + k3 + k4)CE(t) +K5P (t)
dP
dt = k4CE(t)− k5P (t)
(3.3)
in which the rate constants have the same meaning and the
same value of the labeled leucine model. The hypothesis that
the unlabeled leucine is in steady state in both exchangeable
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The fact that the labeled and unlabeled leucine have the same
rate constants is justified by the equivalence of physiological be-
havior of the molecules (no isotope effects are present in the
labeled leucine) and this feature is fundamental for the evalua-
tion of rCPS. In fact, we will show in the next section, the rCPS
is defined from the unlabeled leucine parameter model but we
used the estimated parameters of the labeled leucine model to
calculate it.
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3.2 Parameter estimation of the homogenous
kinetic model
In this section we show how the rate constants (K1, k2 + k3,
k4, Vb) and the variables of interest (λ and rCPS) are estimated
from the data and the homogeneous kinetic model (HOM).
3.2.1 Rate Constant Estimation
For each ROI, including whole brain, the rate constants (K1,
k2 + k3, k4) and the blood volume (Vb) were estimated using
a weighted, non-linear least-squares (NLLS) method to fit the
model equation for total activity (Equation 3.1) to the mea-
sured [11C]leucine activity in plasma, total 11C and 11CO2 activ-
ity in blood, and total activity in the ROI [2]. The equilibrium
brain/blood distribution ratio for 11CO2 was fixed at the value
measured in rhesus monkeys (VD=0.41; [30]), a value in agree-
ment with the mean whole brain/plasma distribution volume de-
termined from 11CO2 studies in humans [4] (The blood/plasma
equilibrium distribution ratio for 11CO2 in human subjects is
close to unity). Weights were inversely proportional to the stan-
dard deviation of the decay corrected activity in each frame
of data. Assuming Poisson statistics, that the counts originate
only in the region itself, and that there are no other noise effects
such as randoms or deadtime, the standard deviation (SD) was
modeled as:





where γ is the decay constant for 11C, ti is the midpoint of
Frame i, ∆ti is the length of Frame i, and N is a coefficient
of proportionality (Demonstration of Equation 3.5 in Appendix
A). The expression used for the representation of the error in
the acquired data is directly correlated with the behavior of
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the tracer in the tissues. Let us consider [11C]Leucine uptake
in brain (Figure 3.3). As we can see from the pictures the L-
[1−11C]leucine needs a period of time to move from the blood to
tissues and, after a peak corresponding the maximum value, its
activity decreases and then changes little with time. Comparing
the two last pictures we note that the noise level increases. This
aspect, due to the decay of 11C, is directly related with the
decreasing number of counts registered by the scanner and so
with the low accuracy that the PET machine has for the last
measures. For this reason in Equation 3.5 there is a term that
refers to the decay of the tracer and the time of acquisition
(eγti): a small number of counts corresponds to a high error in
the measures.
It is important to understand why Equation 3.5 considers
also the time interval of acquisition. The role of ∆ti reflects the
number of the events detected in a period of time: the longer
the acquisition time, the higher the number of counts detected
for that sample. Consistent with this if the period of acquisition
is small also the number of counts is low and so the noise in
that sample will be higher. The law, defined in Equation 3.5,
takes in account all these factors. In Figure 3.4 we can see the
effects of Equation 3.5 in measured data. What is relevant to see
is that the highest weights do not correspond to the data with
highest values but to that with the best compromise between
the quantity of tracer and time resolution. The least weighted
data instead is at the beginning, when there is little tracer in
the tissues or at the end when the tracer activity is low due to
radioactivity decay. Before the estimation of the rate constants,
it is fundamental to correct the data for the delay between the
tracer arrival time in the brain and the arterial sampling site.
For this reason, all the signals used in this work are in advance
corrected from this phenomenon trough a fixed grid approach
(Section 3.3).
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Figure 3.3: The behavior of the tracer decay-corrected in the tissues during
the time. The images are the average of the signals in different intervals [0-2
mins; 2-10 mins; 10-30 mins; 30-60 mins; 60-90 mins]. At the beginning there
is no tracer in the tissues but with the time it starts to arrive. At the end
the concentration of L-[1−11 C]leucine is stationary but we can see that the
images are noisier due to the 11C decay.
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Figure 3.4: The data weighted.
3.2.2 rCPS and λ relationship with the HOM param-
eters
After the kinetic model parameter estimation rCPS can then be







where Cp is the plasma concentration of unlabeled leucine. This
equation comes from the definition of the rCPS, the differential
equations of HOM (Equations 3.3) and the assumption that un-
labeled leucine, in both exchangeable pool and in protein, is in
a steady-state. (In Appendix B all the mathematical passages
to justify Equation 3.6 are reported and explained).
λ, the fraction of leucine in the precursor pool for protein syn-
thesis derived from arterial plasma, can be also expressed in
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terms of the rate constants. The formulation of λ is
λ =
k2 + k3
k2 + k3 + k4
(3.7)
(A complete demonstration, from where this expression comes,
is reported in [28]) In terms of KPatlak, the net uptake rate con-












While rCPS may be directly calculated from Equation 3.6, the
importance of λ arises from its physiologic relevance. Without
knowledge of λ, it is not possible to distinguish whether changes
in rCPS between states/conditions are primary effects or are sec-
ondary to changes in recycling of leucine from tissue proteolysis,
or some combination of the two processes. This was originally
elucidated in the development the L-[1−14 C]leucine autoradio-
graphic method. The high accuracy of estimates of λ using the
L-[1−11C]leucine PET method were confirmed in validation ex-
periments in monkeys [30]. The role of λ becomes fundamental
if we want calculate rCPS with approaches that do not have
access to the rate constants. In those cases the only expression
to quantify rCPS is through the estimation of λ. Some of the
algorithms that we will use in this work will meet this condition.
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3.3 The Delay estimation
In this section we explain how we corrected the data from the
presence of delay in the arterial input function.
3.3.1 The delay correction with a grid approach
The presence of this delay, due to a comprehensive difference
between the tracer arrival in the brain and the arterial sam-
pling site, can greatly influence the goodness of estimates if not
taken into account. For this reason, before appling every kind of
quantification technique, it is necessary to correct the data for
its presence. To do this, we shifted the blood curves in a range
of values and, fitting the whole brain time-activity curve with
a chosen model1, we selected the delay time that produced the
best fit of the data. Weighted Residual Sum of Squares (WRSS)
was used as selection index. The range of possible delays defined
a grid from 0 to 20 seconds with an interval of 1 second.
This approach for the correction is affected by a limit: the
shift of the signal for the delay correction reduces the length of
the blood signals and this could be problematic for the param-
eter estimation. In fact, it is easier to process signals with the
same length than signals with different timeline. To resolve the
problem we applied the delay correction maintaining the origi-
nal length of all the blood curves simply by repeating the last
sample.
Tracer appearance times in various parts of the brain differ
from the mean of the brain as a whole by ±2 seconds [15]. For
this reason, in each study the whole brain tracer arrival delay
value was used for all regions. We reported in the Table 3.1 the
1This approach that we have used for the arterial delay correction requires a model for
the representation of the system to which the data refers. It is not completely clear if the
choice of model affects the estimation of the delay. At the moment, for our analysis the
homogenous kinetic model (Section 3.1) is used.
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Figure 3.5: Typical blood signals measured during the PET acquisition.
Figure 3.6: In this figure we report two blood signals, one delay corrected













Table 3.1: In this table we report the estimates of the delay for the 9 subjects.
The evaluation is based on homogenous kinetic model.
delay values estimated from the subjects considered in this work.
This method for the delay estimation has been used other times
in this work with different modeling approaches. The purpose is
to understand if this delay estimation is affected by the choice
of kinetic model (Section 5.2).
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3.4 The results of NLLS applied to HOM
In Figure 3.7 we report the results of the estimation for K1,
Vb, λ and rCPS in different ROIs. Each value is the average
of the 9 subjects that we considered in this study where the
Standard Deviation (SD) represents the intersubject variability
of the estimates. Looking through the different regions, we can
observe that the values of λ are quite similar, but rCPS that
changes among the different ROIs2, we cannot, however, have
any information about the goodness of the estimates. In fact,
they cannot be compared with anything else because the data
that we used are experimental data and we don’t know a priori
the values of the variables that we estimated with this method.
However we know that this technique has been validated [28]
and at the moment the goal is to estimate rCPS and λ from
L-[1−11 C]leucine PET data.
As an empiric method to understand the capacity of HOM to
describe L-[1 −11 C]leucine data we can compare time-activity
curves with the description provide by the model. In Figure 3.8
there are some examples in different ROIs of one of our subjects.
The graphs show that the fit is not completely good: the data are
underestimated (from 25 to 50 minutes) or overestimated (from
60 to 90 minutes) in all the cases. This behavior is typical of
the homogenous kinetic model and characterizes all the studied
regions. To give an idea about the different accuracy in the
estimates we report in Figure 3.9 the volumes of the ROIs. From
the volume information we can understand the size of the region
and so the noise level associated to it. In fact if the ROI is very
small, like the hypothalamus, the noise in the ROI time-activity
curve is high. Conversely, if the region is large, through the
average the time-activity curve results are very smooth. This
2This information will be useful when we will discuss other kind of compartmental
model for the [11C]leucine system.
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Figure 3.7: NLLS applied to Homogenous kinetic model estimates. Results
are means ± SD for 9 subjects.
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Figure 3.8: Model fit and measured data in two different ROI: whole Brain
and cerebellum. As we can see in all the graphs the behavior of the curves
referred to the model underestimate the data from 25 to 50 minutes and
overestimate the data at the end of the experiment time (around 60 to 90
minutes).
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Figure 3.9: ROI volumes. Each number is the mean ± SD for 9 subjects.
information may in part justify why for regions very small like
hypothalamus or the postcentralgyrus the averaged estimates
present a SD very high compared with the other ROIs.
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3.5 The problem of the HOM: the tissue het-
erogeneity
3.5.1 The reasons of the poor fit
In light of the results shown in the previous section we can say
that the homogenous kinetic model is characterized by some
defects and so it may not be completely reliable for the rCPS
quantification. Probably the causes of these are related to some
hypotheses that are not completely satisfied. In fact, the as-
sumption of tissue homogeneity may not always be a good ap-
proximation for a given region. Rates of blood flow, transport,
metabolism, and incorporation of amino acids into protein, and
therefore also the values of rate constants for each of these pro-
cesses, vary regionally throughout the brain and are particularly
different in gray and white matter tissue. Due to the limited spa-
tial resolution of even the high resolution PET scanner (∼ 2.6
mm FWHM), the thinness of the cerebral cortex (∼ 3-4 mm),
and the white matter tracts that course through subcortical ar-
eas, it is likely that activity measured in most ROIs, and possi-
bly also in many voxels, derives from a heterogeneous mixture
of gray and white matter.
3.5.2 The heterogeneous model
We, therefore, consider a new model, which we will refer to as the
heterogeneous tissue model (HET) (Figure 3.10), that assumes
that each tissue is composed of two homogenous subregions, e.g.,
gray and white matter. The activity in the tissue as a whole can
be expressed as convex linear combination of the activity in its
subregions (a and b), so that the total activity in the volume is
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Figure 3.10: Compartmental representation for the heterogeneous kinetic
model (HET).
given by
C∗T (t) ' (1− Vb)[wa(C∗Ea(t) + P ∗a (t)) + wb(C∗Eb(t) + P ∗b (t))+
+ VD(t)C
∗





wa ≥ 0, wb ≥ 0 and wa + wb = 1 (3.10)
where Vb is the fraction of the region’s volume occupied by blood
and wi is the fraction of the region’s volume occupied by the
tissue i. If subregions a and b are characterized by the parameter
sets [K1a, (k2a+k3a), k4a] and [K1b, (k2b+k3b), k4b], respectively,
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For this model the parameter vector ρ = [waK1a, wbK1b, k2a +
k3a, k2b + k3b,k4a, k4b , Vb]. From Equation 3.11, it is clear that
only six parameters can be estimated with this model - three
coefficients of the integrals, two exponents, and Vb. (Recall that
VD is assumed to be known a priori). The single constraint that
λa = λb, motivated by the observation that regional variation in
λ is small [2], was made to allow the seven (non-independent)
parameters to be estimated. Low regional variation in λ is also
seen in our data (Figure 3.7). Weighted average rCPS in the







k2a + k3a + k4a
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wbK1bk4b





where KPatlak is the net uptake rate constant for [
11C]leucine.
The fraction of unlabeled leucine in the precursor pool for pro-
tein synthesis derived instead from arterial plasma as
λ =
k2a + k3a
k2a + k3a + k4a
=
k2b + k3b
k2b + k3b + k4b
(3.13)
The weighted average influx rate constant for the mixed tissue,
K1, can also be determined as waK1a+wbK1b, but weighted aver-
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ages of the rate constants k2+k3 and k4 are not identifiable from
the estimated parameters since the weights wa and wb are not
known. To estimate the rate constants and thus other variables
of interest from the HET, the same NLLS algorithm with the
same weight data law was used. Possibly due to the large num-
ber of parameteres with HET, however, NLLS did not always
converge. In fact, the NLLS applied to the heterogeneous model
provides different estimates depending of the initial conditions
with which the algorithm is set up and so we obtained differ-
ent estimates for different starting points. Even trying different
set up conditions the presence of a large number of parameters
produces solutions with the same fit of the data but very dif-
ferent from each other and no criterion can be used to decide
which estimate has to be selected as the true solution. In light
of this we cannot be sure of the results provide with the NLLS
applied to the HET: whether they are the true solution for the
estimation, the consequences of convergence to local minimum
or a wrong combinations of parameters that provide a good fit
with the data.
To overcome the limits of the homogenous kinetic model and
to have a corrected instrument for the quantification of rCPS
from L-[1 −11 C]leucine PET data, a new method is necessary.
Our goal is an algorithm that is able to describe the leucine phys-
iology and at the same time to consider the tissue heterogeneity.




4.1 Definition of Spectral Analysis
In this section we define the principles of Spectral Analysis in or-
der to analyze and quantify PET data. This approach represents
an alternative and potentially better method for the quantifica-
tion of rCPS.
Spectral Analysis (SA) is an input-output model to identify ki-
netic components of the tissue tracer activity without specific
model assumptions, like the presence or absence of homogeneity
in the tissue. This technique was introduced by Cunningham
and Jones in 1993 [8] in order to determinate local metabolic
rate of glucose in the brain [36], but now SA is commonly used
with various PET tracers to study physiological systems other
than brain e.g. liver, heart, kidneys, etc . . . ([21]; [20]; [19]).
In SA, the measure of the radioactivity in the tissue at the time
t, Ctiss(t), is modeled as a convolution of the plasma activity















where αj and βj (β1 < β2 < ... < βM+1) are assumed positive or
zero. This constraint derives from the assumption that the SA is
modeling a first order compartmental system. The upper limit,
M+1, represents the maximun numbers of terms to be included
in the model and this is, in general, set to a large number to be
established, usually 100. The values of βj are predetermined
and fixed in order to cover an appropriate spectral range. For
the studies in vivo involving short lived positron emitting iso-
topes this range needs to extend to the slowest possible event
of the tracer in the tissue up to a value appropriate to tran-
sient phenomena (e.g. the passage of activity through the tissue
vasculature).
In general the corresponding term for lim βj →∞ (i.e. βj
with a very large value) is proportional to Cp(t) via αj, and can
be seen as a “high-frequency”component. In the same way the
corresponding term with a βj = 0 or very close is proportional to∫
Cp via αj and can be viewed as a “low-frequency”component,
i.e., accounting for trapping of the tracer. Lastly, the compo-
nents corresponding to the intermediate values βj (intermedi-
ate frequency components) will reflect the uptake of the tracer
within the tissue with their number corresponding to the number
of identificable tissue compartments within the ROI exchanging
with plasma. This number is very important because it gives
an indication of tissue heterogeneity. In light of these particular
features is very common to define SA model equation explicitly
showing the trapping in the following way












To implement the SA model the first step is to define a grid
of βj. The range of the βj, j = 1, 2, ,M can be chosen in dif-
ferent ways, using, e.g., a uniform or logarithmic distribution
of values. In general the “traditional”SA grid follows the Di-
Stefano distribution [18] used for the first time in SA with the
[18F]Fluorodeoxyglucose PET data [36]. The lower limit of this
distribution is defined as β1 = (1/3Tend) where Tend is the end
time of the experiment. The upper limit is provided by βM =
(3/Tin) where Tin is the duration of the first scan (for our specific













with j = 1, 2, ,M and M = 100. The M + 1 unknown values of
the various kinetic components αj are estimated via nonnegative
linear weighted least squares algorithm. For our study this op-
eration has been done using the lsqnonneg.m function included
in Matlab R©(Copyright 1984-2008, the MathWorks, Inc). The
computational time is higher than a linear estimation but the
method is still very fast compared to a non linear approach. The
result of the estimation is called “spectrum”and is represented
in Figure 4.1. In the estimation of the spectrum it is possible
to use a weighted data approach. The choice of the weights de-
pends on the specific features of analyzed data and not on the
estimation algorithm itself.
The precision of αj is determined from the inverse of the Fisher
Information matrix [1] which, from the Cramer-Rao Theorem,
gives a lower bound on the standard deviation (Cramer-Rao
Theorem in [6]).
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Figure 4.1: Example of a possible SA spectrum.
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4.2 The equivalence with to compartmental
models
The standard approach for the modeling PET tracers is based
on compartmental models. Spectral Analysis seems to be a com-
pletely alternative method to this formulation, but this is not
true. The idea behind SA, used by Cunningham in its definition,
was to represent with this new formulation a “generic”compart-
mental model and for this reason there is a very strong correla-
tion between the two techniques. The purpose of this section is
to show this link.
4.2.1 From the compartmental model to the equivalent
spectrum
To show the relation between the various compartment models
and the SA spectrum we introduce some examples. This ap-
proach for the explanation is a less formal to desribe the equiv-
alences between the equations of SA and the equations of the
generic compartmental model, but is simpler and faster. To fur-
ther simplify the equations we initially exclude Vb (the fraction
of the volume occupied by blood) and Cb (concentration of activ-
ity in whole blood) from the model equation. Given our interest
in PET we also adopt the typical conventions of the tracer, e.g.,
the initial concentration in the tissue equals to zero.
First example: a one tissue compartmental model (Figure 4.2A)
In this model, K1 and k2 denote the unidirectional clearance of
tracer from blood to tissue and the rate constant for the transfer
of tracer from tissue to blood, respectively. The equations of the
model are {
C1(t)




Figure 4.2: (A) One-Compartmental model and (B) its relative spectrum




Cp(τ) · e−k2(t−τ)dτ (4.7)
The SA solution equivalent to the compartmental model defines
a spectrum with only one component (Figure 4.2B). The equa-




Cp(τ) · e−β(t−τ)dτ (4.8)
that equals to Equation 4.7 in which K1 is α and k2 is β. If
there is no transfer of the tracer from the tissue of the blood,











This is the typical when in the model a trapping compartment
is present (Figure 4.3). The associated spectrum is still defined
by only one component but the line is located at β = 0. At this
point of the work, it is useful to introduce some terminology,
very common in SA works: when the component is located at
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β = 0 it is called trapping component to indicate the equivalent
trapping compartment; when the component refers instead for
a β 6= 0 it is called equilibrating component and it is related to
a reversible compartment.
Figure 4.3: (A) Compartmental model with trapping and (B) its relative
spectrum
Second example: a two-compartmental model (Figure 4.4A)
Figure 4.4: (A) Two-Compartmental model with trapping and (B) its relative
spectrum
This example is very interesting because it is equivalent to
the homogeneous tissue model for leucine (without the CO2 com-




dt = K1Cp(t)− (k2 + k3)C1(t)
C2(t)
dt = k3C1(t)
y(t) = C1(t) + C2(t)
(4.11)













In this case the spectrum provided by the SA consists of two
components, a trapping component and an equilibrating com-















k2 + k3 = β1
(4.14)
If in the model we include a rate constant for the transfer of
the tracer from C2 to C1, k4, the spectrum changes its config-
uration and what was the trapping component becomes a new
equilibrating component (Figure 4.5B). This behavior is consis-
tent with the change in the model (Figure 4.5A). Obviously the
relationship between the α and β of the new spectrum with the
rate constants is different from the one expressed in Equation
4.14. The new equivalence can be defined from the solution of
the new model.
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Figure 4.5: (A) Two-Compartmental model and (B) its relative spectrum
Figure 4.6: (A) N compartmental model and (B) its relative spectrum
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Third example: N-compartmental catenary model (Figure 4.6A)
This model, with N compartments to describe the processes in
the tissue and one for the blood, is translated in SA with a
spectrum of N components. Each component refers to a specific
compartment. To understand the relationship between com-
partment and component in the two representations we have to
consider the speed of the different processes: the fastest physio-
logical events are associated to the high frequency components
(with the bigger values of betas); the slowest processes instead
correspond to the low frequency components, indicated by a
beta value very close to zero. In general to define the mathemat-
ical relationship from a compartmental model and its equivalent
SA spectrum, the solution of the differential equation system is
required. From this it is very easy to identify the number of
components and the expressions for αs and βs of the spectrum.
But can every model have an equivalent formulation in spectral
analysis? The answer is no. In fact, it has been demonstrated
that the spectral analysis technique can not be used with all
linear compartmental systems [27]. There is in fact a set of
conditions that must be fulfilled for it to be applied. Strongly
connected systems that contain no cycles and for which the ex-
change of material with the environment is confined to a single
compartment are shown to meet the conditions necessary for
application of spectral analysis. Certain weakly connected sys-
tems that include traps as well as non-interconnected collections
of such systems are also shown to meet the conditions. For what
concerns this work, the leucine models meet the criteria for ap-
plication of SA.
Considering the contribution of Vb and Cb in the system, the
measurement equation of the examples defined as
y(t) = Ctissue(t) (4.15)
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becomes
y(t) = (1− Vb) · Ctissue(t) + VbCb (4.16)
The way in which Ctissue(t) is described, does not change. In
fact, if we substitute Ctissue(t) with the equation of the com-
partmental model or its corresponding SA expression, the equiv-
alence between the two method remains the same as described
above.
4.2.2 From the spectrum to the compartmental model
In the previous paragraph we have shown how a compartmen-
tal model can be translated into its equivalent in SA. In this
paragraph instead we do the contrary, i.e. understand what are
the models associated with different spectrums. What we know
about SA is that each component refers at least to one compart-
ment. In this way from the number of lines in a spectrum we
can understand the minimum number of compartments which
are necessary to model a system.
The problem is that the spectrum can not say how the compart-
ments are linked each other. This uncertainty about the connec-
tion knowledge can be shown by an example. Let us consider
a very simple spectrum with only two components: a trapping
and an equilibrating component. The compartmental models
compatible with this situation are two (Figure 4.7) with a com-
pletely different meaning: so what is the model corresponding
to the original spectrum? It’s impossible to answer. The ex-
ample is a very simple situation but the problem becomes more
complicated with increasing numbers of components.
In light of this, without any information about the physiological
system that we are describing it is impossible to determine an
unequivocal correspondence between a spectrum and its equiva-
lent model. Therefore, for each spectrum we can only associate
a class of equivalent compartmental representations which have
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in common the same number of compartments.
Figure 4.7: Two compartmental models. Although they have different con-
figurations, they are both compatible with the same spectrum defined by a
trapping and an equilibrating component.
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4.3 The features of SA method
In this section we present the most important features of SA.
As we have seen this technique does not require that the num-
ber of compartments be fixed before the elaboration, but rather
it provides an estimate of the minimum number of compart-
ments necessary to describe the kinetics of the system. The
SA technique applies to heterogeneous as well as the homoge-
nous tissues: this makes it particularly useful for the analysis
of tracer kinetics in brain with PET because the limited spatial
resolution of the scanner assures that most, if not all, measure-
ments include activities form a heterogeneous mixture of gray
and white matter. Furthermore the SA does not require steady
state conditions for the tracer, unlike the multiple-time graph-
ical analysis technique [24]. The SA also provides an estimate
of the rate constant of trapping tracer in the tissue as well the
amplitudes and decay constants of reversible components. This
information can be used for subsequent specification of a kinetic
model, or it can be used to estimate selected parameters of the
system that do not depend on the specific model configuration,
such as the total volume of distribution of the tracer [8].
However, as we have explained in the previous section, the spec-
trum provides only the minimum number of compartments and
eventually the presence of trapping, but can not say anything
about the configuration of these compartments in the system.
Another important characteristic of the SA method is that it
provides a very good fit between its model description and the
data. This feature is in agreement with the approach that SA
uses for the estimation. In fact only the data, without any prior
compartmental model design of the system, is used to provide
the spectrum and the results are in perfect correlation with it.
The problem is that SA fits the data so well that it tracks the
noise as well, and the results can be corrupted by the pres-
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ence of noise. The consequences of this directly influence the
shape of the spectrum. The presence of noise in the data usually
shifts the components from their true positions and sometimes
can produce non-realistic components called “phantom compo-
nents”. The problem of phantom components in SA is not only
due to the noise, but it also may depend on other factors such
as the distortion present in the arterial plasma signal and the
incapacity of algorithm to clearly distinguish the blood compo-
nent. The effects of these elements in the spectrum are not as
yet completely quantifiable.
About the accuracy, the SA technique has lower precision in
parameter estimates than the compartmental model approach
(Chapter 9). This is due to the large number of parameters of
the SA model equation, number exactly equals to the number of
betas in the fixed grid (∼ 100). The SA precision is also condi-
tioned by the fixed grid. In fact, the position of the components
of the spectrum is limited by the choice of the betas. When the
grid can not adequately approximate the position of the true
components, the algorithm adapts by providing the double com-
ponents. This effect is visible when there are two consecutive
components detected in the spectrum (Figure 4.8). Due to the
discrete nature of the grid, the algorithm can not place all the
components in their correct positions, but only at betas defined
by the grid. Sometimes to improve the fit of the data the algo-
rithm splits the components in two parts placed in the closest
possible positions of the best-fitting value. To resolve the prob-
lem we defined a very simple correction. In case of double com-
ponents as Compj(βj;αj) and Compj+1(βj+1;αj+1), a new com-
ponent CompNEW (βNEW ;αNEW ) is calculated to replace Compj
and Compj+1 in the spectrum. Following a weighted average ap-
proach βNEW and αNEW are defined as
αNEW = αj + αj+1 (4.17)
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Figure 4.8: Double effect correction
βNEW =
βj · αj + βj+1 · αj+1
αj + αj+1
(4.18)
The original spectrum and its corrected spectrum are obviously
different but the curves, which they refer to, are so close that
can not distinguished. In Figure 4.9 we can have an idea of how
this kind of correction influences the signals trend.
Figure 4.9: Signal with (Red line) and without (Green line) the double effect
correction.
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The last relevant characteristic of SA is related to the computa-
tional time. The SA model is linear, so in theory the spectrum
can be easily evaluated by a linear estimation method with a
very high computational efficiency. But, for the non-negativity
restriction of the αs, this is not possible to do and only minimiza-
tion algorithms that implement this condition can be used with
a consequent increase of computational time. However, these
methods still have a very good efficiency and are extremely fast
compared to the non linear methods. The non-negativity re-
striction is fundamental for the SA method. In fact, without
this condition, we will obtain for a single estimation hundreds
of different equivalent solutions with the same fit of the data.
In all these spectra the negative components will eliminate the
effects of positive ones and vice versa and so we will not have
the typical spectrum of SA in which only the real components
of the data are visible because they are different from zero. In
Figure 4.10 we report an example.
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Figure 4.10: An example of SA estimation without non-negativity constraint.
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4.4 Quantification and Choice of model
Depending on the information that we want extract from the
data, the Spectral Analysis can be used in two different ways.
The first approach is related to the quantification of the vari-
ables of interest and consists of the arrangement of the spectrum
lines. Different examples of PET SA quantification have been
used in different organs and for different tracers ([21]; [20]; [19];
[37]). To do this, a mathematical expression that explains the
link between the variables of interest and the spectrum com-
ponents is necessary. Usually this expression is defined using
the relationship between the variables and the compartmental
model, and the relationship between the compartmental model
and SA. The system of equivalences is shown in Figure 4.11.
Another way to use SA is for the definition of the most ap-
Figure 4.11: In this scheme the relationships between SA and compartmental
model, compartmental model and variables of interest, and between SA and
variables of interest, are shown. In particular, the red arrow indicates the
relation used for the SA quantification.
propriate compartmental model to describe a set of data. In
particular, SA is useful to determine the number of compart-
ments present in a system, because as we explained previously
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it can not say anything about their connections. This kind of
approach could resolve the problem in leucine modeling. In fact,
without any reliable results for the heterogeneous model iden-
tification, the SA could demonstrate if HET is better or worse
than the homogenous model. In this way we could also quan-
tify a measure of the heterogeneity in the tissue. To use the
SA with this purpose a different approach to the standard SA
implementation method is required. In fact, if the aim of SA is
to find the number of exponential components of the system im-
pulse response without having to define a structure beforehand,
defining a grid of eigenvalues βj and estimating only the relative
amplitudes αj is not necessary. The right approach to follow is
simply to estimate M the number of exponentials necessary for
the SA equation (Section 4.3, Equations 4.1- 4.3) to give a good
fit to the data by using models of increasing order. For instance,
one can start first with a one-exponential model
CT (t) = α1 · Cp(t)⊗ e−β1t (4.19)
and estimate by Weighted NLLS the parameters. Then trying
a two-exponential order, with one trapping component
CT (t) = α1 ·
∫
Cp(t) + α2 · Cp(t)⊗ e−β2t (4.20)
and then with two equilibrating components
CT (t) = α1 · Cp(t)⊗ e−β1t + α2 · Cp(t)⊗ e−β2t (4.21)
and so on. The standard model parsimony criteria techniques
[13] can be used to choose the best model. This way of applying
SA has as an additional bonus: not only the standard deviation
error of the αs estimates, but also the precision of the βs are
provided. In fact, if the betas are selected from a predetermined
grid, as in the standard SA approach, it is impossible to obtain
a measure of their precision. Finally, estimation of the βj avoids
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the problem of the doubling.
In light of these considerations, this new SA approach provides
a statistically model-independent information which can guide
the selection of the most appropriate among the potential com-
partmental candidate structures. For our specific case, about
the leucine PET data the candidate models are represented in
part from the homogenous and heterogeneous models, but SA
may find other solutions. As we know, the SA is extremely help-
ful to discriminate among potential compartmental models, but
it does not give a unique answer and more than one structure
may be compatible. To select the correct solution we will use
known information about the leucine kinetics.
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Chapter 5
The SA fixed model approach
5.1 The choice of the model for leucine PET
data
In this section we apply the Spectral Analysis method to under-
stand what compartmental representation is the best to describe
the leucine PET data. To do this we used the SA approach for
the choice of the model described in (Section 4.4). Six SA fixed
models were selected as possible solutions: 3 with the trapping
component and 3 without. The six equations of these models
are reported below:
Model 1 (1 Equilibrating Component):
CT (t) = α1 · Cp(t)⊗ e−β1t (5.1)
Model 2 (1 Equilibrating Component +1 Trapping Component):
CT (t) = α1 ·
∫
Cp(t) + α2 · Cp(t)⊗ e−β2t (5.2)
Model 3 (2 Equilibrating Components):
CT (t) = α1 · Cp(t)⊗ e−β1t + α2 · Cp(t)⊗ e−β2t (5.3)
Model 4 (2 Equilibrating Components +1 Trapping Compo-
nent):
CT (t) = α1 ·
∫
Cp(t)+α2 ·Cp(t)⊗e−β2t+α3 ·Cp(t)⊗e−β3t (5.4)
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Model 5 (3 Equilibrating Components):
CT (t) = α1·Cp(t)⊗e−β1t+α2·Cp(t)⊗e−β2t+α3·Cp(t)⊗e−β3t (5.5)
Model 6 (3 Equilibrating Components +1 Trapping Compo-
nent):




All these models have been estimated through NLLS applied
to leucine PET data. All the available ROIs for all the sub-
jects have been examined. In the next paragraphs we report the
results of this estimation.
5.1.1 The fit of the data
In Figure 5.1 we compare the differences between the measured
data and the descriptions provided by the different models in
the whole brain. Some of the models are not able to explain
the data. These ineffective models (Fig 5.1A and 5.1E) do not
include the trapping for the tracer. The others (Figure 5.1B,
5.1C, 5.1D and 5.1F), seem to show the same goodness of fit
even though in Figure 5.1B and 5.1D the tails of the model-
estimated curves do not fit as well as 5.1C and 5.1F.
5.1.2 The weighted residual trends
In Figure 5.2 we report the weighted residual trends for the
whole brain PET data. The six pictures refer to the 6 models.
The weighted residuals are obtained from the multiplication of
the residuals with the data weights. If the estimation is good,
the difference between the model-estimated and the measured
data should be a representation of a white noise process1, that
1White noise is a random signal (or process) with a flat power spectral density. In other
words, the signal contains equal power within a fixed bandwidth at any center frequency.
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Figure 5.1: Different fit for different SA fixed model estimation. From Figure
5.1A to Figure 5.1G, we have in order the fit of the data with 1 eq model, 1
eq + trap model, 2 eq model, 2 eq + trap model, 3 eq model, 3 eq + trap
model. We can see that only the presence of trapping compartment in the
model can explain the data. In particular the graphs A and E show how the
models that lack this feature fail completely to describe the measured data.
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means that the residuals should be random and in the range
[−1; 1]. The models associated at the pictures A and E do not
present this behavior, and like Figure 5.1, do not agree with
a good estimation. The others, instead, seem to be consistent
with the expected trend.
5.1.3 The distribution of the components
In Figure 5.3, we report the distribution of the components de-
tected in 9 subjects for the whole brain. Each picture refers to
a different model. What we can see is that every distribution
reports the presence of the trapping for all the subjects, even in
those models in which is not explicitly defined. Also looking at
the three distributions below we can see more or less the same
trend, namely, it appears that one trapping an two equilibrating
components are required.
5.1.4 Comparison through the Akaike Index
In Figure 5.4 we provide a comparison between the Akaike Infor-
mation Criterion (AIC) indexes calculated from the different
models. The values are the average between the subjects, de-
fined for all the ROIs and for all the chosen models. As we can
see, the best results come from the models with a trapping com-
partment and one or two reversible compartments. Considering
the kinetics of leucine, these spectra are compatible with the ho-
mogenous (Section 3.1) and heterogeneous (Section 3.5) kinetic
models, respectively. It’s important to emphasize that in some
regions (corona radiata and cerebellar white matter) the best
solution coincides with the model with two equilibrating com-
White noise draws its name from white light in which the power spectral density of the
light is distributed over the visible band in such a way that the eye’s three color receptors
(cones) are approximately equally stimulated. In statistics white noise is referred to a
random process with mean = 0 and SD = 1.
64
Figure 5.2: Weighted residuals in SA fixed model estimation. From figure A
to figure G, we have in order the weighted residuals trend about 1 eq model,
1 eq + trap model, 2 eq model, 2 eq + trap model, 3 eq model, 3 eq + trap
model. This kind of representation adds information about the goodness of
the estimations. In fact, if the estimation is good, the trend of weighted
residual should be random and between [−1; 1]. In particular we see that
graphs A and E do not have this characteristic to underline again that the
quality of estimation with these two models is very poor. The other ones
have the expected trend.
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Figure 5.3: Different distributions of components in SA fixed model estima-
tion. The histograms represent the distribution of the betas in 9 subjects.
The picture shows how the trapping is necessary to explain the data. In fact
there’s always an important presence at α = 0 or very close to it even when
the model does not explicitly include trapping. The two last graphs on the
bottom have a behavior very similar to the model 2eq + trap even though
they have the freedom to assume other forms. This suggests that a model
with a trapping and two reversible compartments may be the best solution.
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ponents but, for these cases, the slowest component is so close
to zero that it can be considered a trapping compartment. Also
sometimes the differences between the models are very small,
and more than one choice can be selected.
5.1.5 The Final Choice
Considering all the results shown above, we can conclude that
the presence of trapping is necessary to explain the behavior
of L-[1 −11 C]leucine PET data. In fact, without it, unreal-
istic trends of residual and incompatible fits of the measured
data are provided. When the trapping is not specified in the
model, in the spectrum the slowest component shifts very close
to zero, indicating that this component is required to describe
the data. This feature is fundamental because it suggests that
the behavior of the L-[1−11C]leucine is consistent with our pur-
pose to study protein synthesis. In fact, if the trapping were
not included in the model of L-[1−11C]leucine kinetics it would
indicate that the tracer would be unsuitable for rCPS quantifi-
cation.
Looking to the distribution trends and the Akaike comparison
we can see that the best model requires the presence of hetero-
geneity in the tissues. However, in some few regions HOM is
selected as the best data representation. This does not mean
that for these ROIs we can exclude the presence of the tissue
heterogeneity but some reasons (probably the small size of the
ROI) may allow a homogenous representation as well as a het-
erogeneous one. In fact, for these particular regions the AIC for
HOM is very similar to AIC for the HET.
Sometimes several models have an equivalent capacity to de-
scribe the same data and the choice of a best model is not so
simple, but in light of the considerations about heterogeneity,
and the results that we have shown the heterogeneous kinetic
67
model seems to be more reliable to describe the time curses of
measured activity.
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Figure 5.4: Akaike Information Criterion (AIC). The results are the means
± SD for the 9 subjects.
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5.2 The delay estimation with SA fixed model
Using different SA models (Equations 5.1 to 5.6) we re-estimated
the time delay between tracer arrival in the brain and at the ar-
terial sampling site. Our purpose was to understand if there
are some correlations between the models used for describing
the data and the estimates of the tracer delay. For the quan-
tification of tracer delay, we used the same approach with fixed
grid that was utilized for the homogeneous tissue model (Sec-
tion 3.3). In Figure 5.5 we report the results of the tracer delay
Figure 5.5: Tracer arrival delays estimated with different models. For each
subject the results are in very good agreement, except for the model with
only one reversible compartment (1 Eq).
estimation. We can see a good agreement between the different
approaches for each subject, except for the values provided by
the model with only one reversible compartment (1 Eq). We
know, in fact, that this model is not feasible to describe the
data (Section 5.1). It is interesting to emphasize that different
models, the heterogeneous as well as the homogeneous, give com-
parable delay estimates. This feature is true for all the subjects.
Therefore, the tracer delay estimation can be considered model
independent for all the model representations with a sufficiently
good fit of the measured data.
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Chapter 6
The Standard SA approaches
6.1 The mathematical relationship between
the spectrum and variables of interest
In this section we present the relationship that exists between
the components provided by SA in the analysis of L-[1 −11 C]-
leucine PET data and the variables of interest, in particular,
λ and rCPS. To do this we show how each possible evaluated
spectrum can be linked with its corresponding compartmental
model and through this equivalence we describe the mathemat-
ical expressions that relate the αs and βs to the variables of
interest.
6.1.1 First example: A spectrum with one trapping
and one equilibrating component
As we have shown in previous chapters this kind of spectrum,
in the particular case of L-[1 −11 C]leucine PET data, refers to
the HOM (Section 3.1). From this model we know that rCPS













Figure 6.1: A spectrum with two components: one trapping and one equili-
brating component.
where Cp is the arterial plasma concentration of unlabeled leucine,
Kpatlak is the net uptake rate constant for [




k2 + k3 + k4
(6.2)
From the relationship between the homogenous model and SA
(Section 4.2) we know also that
K1k4
k2 + k3 + k4
= α0 = KPatlak (6.3)
and
K1(k2 + k3)
k2 + k3 + k4
= α1 and k2 + k3 + k4 = β1 (6.4)
Equations 6.3, 6.4 define the equivalence between the spectral
components and the model for the trapping and the reversible
compartment respectively. There are some notation differences
between the leucine homogenous model (Chapter 3) and the
standard homogenous model (Chapter 4). The equivalence of
the parameters is provided by the following table.
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Homogenous leucine model Standard homogenous model
K1 K1
k2 + k3 k2
k4 k3
Table 6.1: Equivalence between Homogenous leucine model and Standard
homogenous model.
Using this relationship we translated the equations for equiv-
alence between SA and the homogeneous standard model (Equa-
tions 4.11-4.14) to the ones for the equivalence between SA and
HOM (Equations 6.3- 6.4).
We can observe that from the sum of the αs we have





k2 + k3 + k4
= K1 (6.5)
Substituting Equation 6.2 for λ into Equation 6.4 we have
α1 =
K1(k2 + k3)
k2 + k3 + k4
= K1
k2 + k3
k2 + k3 + k4
= K1 · λ (6.6)

















α0 · (α0 + α1)
α1
Cp (6.8)
Equation 6.8 shows the relationship between the spectrum and
the parameters of interest that we were looking for.
6.1.2 Second example: A spectrum with one trapping
and two equilibrating components
Among all the possible compartmental models compatible with
the considered spectrum, we can easily observe that for the char-
acteristics of the tracer only HET (Section 3.5) is consistent with
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Figure 6.2: A spectrum with three components: one trapping and two equi-
librating components.

















k2a + k3a + k4a
=
k2b + k3b
k2b + k3b + k4b
(6.10)
Considering Equation 3.11 we can formulate the link between
the spectrum and the model as
α0 = KPatlak =
(
waK1ak4a
k2a + k3a + k4a
+
wbK1bk4b






k2a + k3a + k4a
)




k2b + k3b + k4b
)
and β2 = k2b + k3b + k4b (6.13)
with
wa ≥ 0, wb ≥ 0 and wa + wb = 1 (6.14)
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αj = α0 + α1 + α2 = waK1a + wbK1b = K
∗
1 (6.15)
where K∗1 is the weighted average of K1. Defining
λa =
k2a + k3a




k2b + k3b + k4b
(6.17)
if we make the assumption that
λa = λb = λ (6.18)
we obtain∑2
j=1 αj = α1 + α2 = waK1aλa + wbK1bλb =










α0 + α1 + α2
(6.20)








α0 · (α0 + α1 + α2)
α1 + α2
Cp (6.21)
6.1.3 Third example: A spectrum with one trapping
and N equilibrating components
Let us consider a spectrum with one trapping and N-equilibrating
components. This spectrum is consistent with leucine PET data
in which we have N different tissues mixed together, and each
tissue contains one trapping and one equilibrating component.
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Figure 6.3: A spectrum with (N+1) components: one trapping and N-
equilibrating component.
A possible compartmental representation, therefore, can be de-
fined by generalizing the heterogeneous model (Figure 6.4). To
calculate the expression for the rCPS and λ depending on the
αs and βs of the spectrum we can repeat the same procedure of
the previous example.
1. The variables of interest are expressed from the compart-



















2. The parameters of the spectrum are related to the rate
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Figure 6.4: The generic heterogeneous model for the L-[1−11C]leucine PET.
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constants as











k2a + k3a + k4a
)




k2b + k3b + k4b
)





k2N + k3N + k4N
)
and βN = k2N + k3N + k4N
(6.27)
with





k2j + k3j + k4j










4. We furthermore assume that λ is the same in all tissues in
the mixture, i.e.,
λj = λ∀ with j = a, b, . . . , N. (6.31)
5. The sum of all α’s corresponding to the equilibrating com-
ponents is given by∑N
j=1 αj = waK1aλa + wbK1bλb + · · ·+ wNK1NλN =
= (waK1a + wbK1b + · · ·+ wNK1N)λ = K∗1λ
(6.32)
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6.1.4 Solutions for a generic spectrum
The last expressions of the previous paragraph (Equations 6.33,
6.34), give a powerful mathematical tool to calculate rCPS and
λ from every spectrum estimated from leucine PET data. To
arrive at these equations, it’s important to emphasize two as-
sumptions that were made.
The first is the presence of the trapping component. In fact,
as we have seen in Chapter 5, in the analysis of the leucine
PET data, the trapping is indispensable for describing the data.
Without this feature the estimated data provided by the model
is unrealistic, compared with the measured data. If the trapping
is not present in the spectrum, it is possible that the presence
of noise and some other errors in the data shift this component
into a nonzero position. For this reason, when this happens we
consider the lowest frequency component as trapping.
The second assumption concerns the equivalence of lambda in
the different tissues. This hypothesis, even though reasonable,
may not be completely true. In fact, we know that the variability
of λ in the different regions is low [2], but we must keep in mind
that these estimates of λ were based on a homogenous tissue
model which may not adequately describe the data. However,
without a measure of the heterogeneity in the tissues that allows
to measure the weights wi, this simplification is necessary to
provide the relationship between the spectrum and the variables
of interest.
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In light of these considerations, however, the Equations 6.33,
6.34 provide a reasonable mathematical tool to relate every kind
of spectrum with the variables of interest. We will use this
approach to estimate rCPS and λ, from each spectrum provided
by each of the SA techniques that we present in this and the
following chapters.
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6.2 The Cunningham SA Method
6.2.1 The method
The first Spectral Analysis approach that we used for the quan-
tification of the variables of interest is the Cunningham method
[8]. This approach consists of applying the SA as it is defined
without any filtering of the data or of the spectrum. Considering
the context of leucine PET data, we adapted the equation of SA
model (Section 4.1) to the equation of the total activity in the
ROI (Equation 3.2). In fact, if the total radioactivity detected
by the PET scanner can be expressed as
Cmeasured(t) = (1−Vb) · [Ctissue(t)+VD ·Cc(t)]+Vb ·Cb(t) (6.35)
then using the SA equation we can write 6.35 as
Cmeasured(t) = (1− Vb) · [
M∑
j=0
αj ·Cp(t)⊗ e−βjt+ VD ·Cc] + Vb ·Cb
(6.36)
where
β0 = 0. (6.37)
From 6.36 we estimated directly the values of αs and Vb using
the lsqnonneg.m Matlab function, and from the results we cal-
culated rCPS and by Equations 6.33, 6.34.
It is useful to emphasize that to apply lsqnonneg.m function the
measurement equation expressed in 6.36 has to be arranged in a
different way. This is due to the presence of the term VD ·Cc(t),
whose value is known, between the unknown parameters. To
resolve this problem we defined
α∗j = (1− Vb) · αj (6.38)
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j · Cp(t)⊗ e−βjt]+





j · Cp(t)⊗ e−βjt]+
+ VD · Cc(t) + Vb · [Cb(t)− VD · Cc(t)]
(6.39)
Subtracting the VD · Cc(t) known value from the data we can
write a new equation from which it is now possible to apply
directly the estimation function
Cmeasured(t)





j · Cp(t)⊗ e−βjt] + Vb · [Cb(t)− VD · Cc(t)]
(6.40)





Without this arrangement, which does not violate the principles
of SA methods, it is not possible to evaluate directly the values
of αs and Vb using the lsqnonneg.m function.
6.2.2 Results
We report the rCPS results provided with Cunningham SA and
compared with the NLLS-HOM estimates (Figure 6.5). The val-
ues are in complete disagreement. The rCPS estimates are very
different and also the SA intersubject variability, expressed by
the SD or the CV, is not reasonable (CV is about 50% for all
the regions). In Figure 6.6 we have a graphic representation of
the results. We can see again that there is no correspondence
between the Cunningham SA estimates and the ones calculated
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with the HOM approach. In particular, the rCPS values mea-
sured with SA are largely underestimated, and even including
the SD, there is no match between the methods. The same ob-
servations can be formulated from Figures 6.7 and 6.8 in which
the specific estimates in one of the 9 subjects provided by the
two methods are compared. As for the averages, rCPS is under-
estimated with the Cunningham approach.
6.2.3 Considerations
In light of the results, the Cunningham SA approach for the
quantification of rCPS can not be considered a valid instrument.
There is necessarily something wrong in the procedure of esti-
mation. The first thing to check is the capacity of the SA to
explain the data. In Figure 6.9 we report the fit between the SA
model and the data in the noisiest region (hypothalamus) and in
the least noisy ROI (wholebrain). According with the different
levels of noise the trends provided by the SA model are good and
explain the data very well. Probably, the causes of the failure of
the Cunningham SA in the analysis of leucine PET data are due
to something uncorrected in the spectrum. In fact, the values
for the trapping components are not what we expected from the
NLLS-HOM estimates. For these reasons, the application of a
filter in the spectrum, as defined by the Turkheimer SA, may
improve the quality of the results.
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Figure 6.5: rCPS (nmol/g/min) estimated by the Cunningham SA method
and NLLS fitting of the data with HOM. Values are means ± SD for the 9
subjects.
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Figure 6.6: Bar graph of the rCPS averages in all ROIs quantified with
NLLS-HOM method (red bars) and Cunningham SA (blue bars).
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Figure 6.7: Comparison of the rCPS (nmol/g/min) estimates for NLLS-HOM
method and Cunningham SA. The results refer to one of the 9 subjects of
the study.
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Figure 6.8: Bar graph of the rCPS distribution in all ROIs quantified with
NLLS-HOM method (red bars) and Cunningham SA (blue bars). The values
refer to one of the subjects.
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Figure 6.9: The graphs report the fit and the spectrum provided with Cun-
ningham SA in one subject. The group A is related to the hypothalamus,




In order to overcome the limits of Cunningham SA technique for
the quantification of λ and rCPS in leucine PET data we seek
to improve the Spectral Analysis estimation algorithm with the
Turkheimer filter. This approach consists of the application of a
simple numerical filter for the spectrum provided with the Cun-
ningham SA. With this method, all the identified components,
with exponents greater than zero but less than βcut−off are as-
sumed to have been shifted from β0 due to noise in the data, and
the remaining components with exponents greater than βcut−off
are assumed to correspond to real equilibrating processes in the
system. To compute α0 with this filter, the blood component
and all the identified equilibrating components whose exponents
are higher than βcut−off are subtracted from the total radioactiv-
ity data to obtain the integrated component, α0
∫
C∗p(t)dt, plus
noise. A linear least squares procedure is then used to estimate
α0 as the slope of the graph of the integrated component versus∫
C∗p(t)dt.
The first consequence of the Turkheimer filter is to “clean”the
spectrum from the influence of noise, in particular for what con-
cerned the low frequency components and the trapping, and so
to obtain a better solution than the no-filter SA. The role of
βcut−off is fundamental because it decides where the noise ends
and the real components start.
Although the improvement provided by the Turkheimer SA is
important, this filter can not be sufficient for the particular case
of rCPS quantification in leucine PET data as will be shown
in this section. In fact, unlike the common SA application for
estimation of the rate of regional cerebral glucose utilization
(rCMRglu), in which only the value of the trapping was used
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for quantification of the variables of interest (i.e. no correction
for blood in the brain was made), we have seen that for the
evaluation of λ and rCPS all the components of the spectrum
are required (Section 6.1). For this reason, the entire spectrum
has to be corrected for the noise effect, the high frequency com-
ponents as well as the low ones. Therefore, we have elaborated
a double Turkheimer filter to make this kind of spectrum cor-
rection in the entire range of frequencies.
The double Turkheimer filter uses the same approach as the sim-
ple one but with two βcut−off , a low and a high value, that iden-
tify what is called the cut-off interval. The goal of the method is
to eliminate all the components outside this interval and thereby
improving the quality of estimation for the trapping component,
in the low side of the spectrum, and for the Vb, which does not
belong properly to the spectrum but can be confused with high-
frequency components. To do this, the double filter Turkheimer
method uses the same simple filtering: the contribution of the
components located inside the cut-off interval is subtracted from
the measured data; from the result new values of α0 and Vb are
estimated through a linear least squares algorithm. This change
sounds reasonable and robust with the particular characteris-
tics of the data: reasonable because in this way we corrected
the spectrum at low and high frequencies; robust because the
α0 and Vb have so different influences in the data that cannot be
confused in the filtering estimation process. The cut-off inter-
val has the same importance as the single βcut−off in the simple
filtering. It selects what part of the spectrum is consistent with
true kinetic processes and what is not, and for this reason choice
of the interval is very critical for the final results.
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Figure 6.10: A graphical representation of the simple and the double
Turkheimer filtering
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6.3.2 The simulation experiment
Before applying the SA with the Turkheimer double filter to
the measured data we have tested the characteristics of the al-
gorithm in simulation studies. The idea that we followed was
to define a dataset as realistic as possible, and for this data
understand the behavior of the double filter under different con-
ditions. The spectrum from which we generated the simulated
signals was chosen from the previous analyses of the HOM and
HET results. From these estimates we selected a spectrum
with two equilibrating components, one trapping component
and Vb = 0.05 (Figure 6.11). For these values, αs, βs and
the corresponding variables of interest have been calculated the
Equations 6.33, 6.34 (Figure 6.12). Then 1,000 realizations of
Figure 6.11: Simulated spectrum
Figure 6.12: Simulated variables of interest
noisy signals have been generated using for the arterial plasma,
the 11CO2 and the whole blood activity from blood samples mea-
sured in one of the subjects of the study, and for noise the same
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statistical description that as was used to weight the data (Chap-
ter 3).
From this dataset we estimated the variables of interest under
the following conditions as:
• Different numbers of βs on the grid (to evaluate phantom
components)
• Different grid choices (DiStefano or Logarithmic)
• Different cut-off values
• Different noise levels
• Different signal lengths (60, 75, or 90 mins)
The estimates among all the simulated signals have been com-
pared with the simulated values of Figure 6.12 in order to un-
derstand the quality of the results and the characteristics of the
algorithm. We used as performance indexes:
• The Averages of variables of interest compared with simu-
lated values (to understand Bias)
• The Parameter distribution (histogram shape, standard de-
viation)
• The Component distribution (histogram shape compared
to the simulated spectrum)
6.3.3 The simulation results
In this part we report the results for the SA with double Turkheimer
filter for the different simulated conditions.
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Different numbers of betas on the grid
We tested 3 grids with 50, 100 and 200 betas, respectively, but
we did not see any difference in the estimates and in the distri-
butions of the parameters. We could only see a slightly more
accurate component distribution for the 200-beta grid that, how-
ever, had a higher computational time cost. We decided to use
100-beta grid because it represents a good compromise between
results and processing time.
Different grid choices
In Figure 6.13 we show the different distribution of betas with
DiStefano and two logarithmic grids. For the low frequency be-
tas the grids have the same density of samples and it is impos-
sible to distinguished one from the others. In the high frequen-
cies side, instead, the grids present different beta distributions.
However, this difference does not influence the detection of the
spectrum because the components of the simulated data belong
to the low frequency side. Therefore they can be detected with
the same accuracy with all the three kind of tested grids. We
finally decided to apply always in this work the DiStefano distri-
bution to follow the standard convention typical of SA studies.
Different values for the cut-off interval
This is the most interesting part of the simulation study because
it links the filter bounds with the final results of the estimation.
In particular, we are interested in finding the optimal choice for
the cut-off interval, i.e. the filter that provides the best esti-
mates, i.e., those with low bias and a low standard error. This
choice is fundamental for our study because the value selected
based on the simulation experiment will be applied to the anal-
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Figure 6.13: Comparison between different grid distributions. The first 50
components of grids represent quite similarly the same range of spectrum
and so for the SA estimations are equivalent.
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ysis of the measured data, as we have no other basis on which
to decide the best cut-off value to use. To determine this best
solution we tried different bound values for both the sides of
the filter interval. These values were chosen taking into consid-
eration the frequency of the blood sampling and the duration
of the experiment in order to define the slowest and the fastest
component detectable from the data.
Figure 6.14: The histograms represent rCPS and λ distributions for one of
the selected cut-off intervals. The quality indexes for the estimates have to
take in account the bias as well as the distribution of the results. In the
shown cases, in fact, the average bias is very low but the distributions have
high variance.
Different noise levels
In this section we report the results of the simulations with
different levels of noise. The signals were defined using the same
expression used for the description of the data error (refer to
the law of the error). The range of the noise was modulated
through the scale factor N. For the other simulations this value
was set to 0.5 comparable to a mid level for a ROI, but, in this
particular case, N was changed in a range comparable with the
lowest to highest possible noise level present a ROI. The results,
as we expected, show that the bias and the standard deviation in
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estimates of the variables of interest are inversely related to the
level of the noise, but even for the nosiest signals they assumed
acceptable values.
Different Data Acquisition lengths
This simulation provides information regarding the minimal time
of data acquisition necessary to obtain accurate estimates for
our variables of interest. The question that we want to answer
is if we can obtain the same quality of estimates with a shorter
duration of the PET data acquisition: shorter data acquisition
would be an obvious advantage for the comfort of the patient.
For this reason the algorithm has been applied to signals of 60,
75 and 90 minutes length using as cut-off interval the optimal
choice selected from the simulation.
The results provided by the SA with the double Turkheimer fil-
ter show that without a length of 90 minutes the bias of the
estimates became quite high (Figure 6.15).
Figure 6.15: λ and rCPS estimates in different data lengths. The results are
the mean ± SD for 1,000 simulated signals.
6.3.4 The application of the SA with double Turkheimer
filter in measured data
The results obtained from the simulations with the Turkheimer
double filter are not as good as expected, but, with the optimal
value of the cut-off interval, this method can provide acceptable
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values for the estimates. This behavior justifies its application
for the quantification of the variables of interest in measured
data. In Figures 6.16,6.17 and 6.19 we report the results for
our 9 subjects. The data represent mean and SD for the 9
subjects. Even though the means are be generally consistent
with the NLLS-HOM results, the SD, in particular for the rCPS
and λ, is extremely high (the inter-subject variability is more
than 100% of the mean). To acquire more information about
the Turkheimer SA behavior, as we have done for the NLLS-
HOM and for the Cunningham SA, we considered the fit of the
model with the data. An example is shown in Figure 6.18: what
was a perfect agreement with the data in the Cunningham SA is
now completely lost. We have, in fact, an underestimation and
an overestimation of the measured that is similar to a HOM fit.
In light of these results we can say that the application of SA
with the double Turkheimer filter for the leucine PET data is
not a useful method.
6.3.5 Considerations
The results provided by the Spectral Analysis with the double
Turkheimer filter are unacceptable as were the Cunningham SA
estimates. Although the Cunningham SA method does not pro-
vide correct estimates for the variables of interest, the fit of the
data was very good. With the Turkheimer filter, instead, we lose
this characteristic. The reason may be related to some facet of
filtering process. In particular, the fit with the data seems to
suggest that there is something similar to the HOM model be-
havior. In fact, in the trend of the Turkheimer SA estimated
signal (Figure 6.18) there is the same under and overestima-
tion typical of the homogenous tissue kinetic model. Looking
at the spectrum before and after the filtering we observed that
the correction made by the algorithm changes the number of
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Figure 6.16: SA with double Turkheimer filter. The results are the mean ±
SD for 9 subjects.
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Figure 6.17: SA with double Turkheimer filter. The results are the mean ±
SD for 9 subjects.
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Figure 6.18: SA with double Turkheimer filter. Fit of the Whole Brain
measured data of one subject.
Figure 6.19: Bar graph of the rCPS averages in all the ROI quantified with
NLLS-HOM method (red bars) and Turkheimer SA (blue bars). Lines show
inter-subject standard deviation.
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the equilibrating components. In most of the simulated cases
in which the pre-filtered spectrum was comparable with a het-
erogeneous representation, we finally obtained after the filtering
a spectrum equivalent to a homogenous representation (Figure
6.20). The cause of this problem is related at the filter imple-
Figure 6.20: Representation of the SA with the Turkheimer double filter
effect in the fitting of measured data.
mentation (Figure 6.20). In fact, with the approach that it uses
the components outside the cut-off interval are eliminated for a
new value of the trapping and Vb. But this is not completely
correct. In fact the presence of these components is, in part,
due to the presence of noise, in part due to the trapping and
Vb, but for another part due to real equilibrating components
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that we have to take in account if we want to describe the data
correctly. This mistake will be resolved with the introduction of




A new Spectral Analaysis
algorithm
7.1 The Spectral Analysis Iterative Filter (SAIF)
7.1.1 Introduction
To overcome the limits of the “standard”Spectral Analysis tech-
niques such as the Cunningham method and the Turkheimer
double filter approach, we developed a new Spectral Analysis
algorithm with the purpose of providing good quality estimates
of rCPS and λ from leucine PET data. Our starting point for the
definition of this new method was the Turkheimer SA method
and its limitations. As we have seen in the previous chapter
(Section 6.3) the components that we eliminated from the origi-
nal spectrum with the filtering were due to a mixture of effects:
1. the presence of noise and errors into the input function
signal1;
2. the trapping and the blood volume that could not be clearly
detected;
1The input function used for the quantification of the variables of interest is an ap-
proximation of the true plasma signal. Even though we corrected the blood samples for
the tracer arrival delay we did not take in account other phenomena as the “distortions”
introduced by the vessels geometry.
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3. the presence of real equilibrating components of the system.
The Turkheimer SA, instead, does not consider for the slowest
components the third possibility2 and this may be the origin of
the strange fit between the model estimated curves and uncor-
rected estimation of the variables of interest. The new method
takes into account all these contributions that influence the spec-
tral component detection in the normal SA. To accomplish this,
we defined a correction filtering composed of two parts. In the
first, using the same procedure as the double Turkheimer fil-
ter: we remove the equilibrating components and new values of
the trapping component and Vb are estimated. In the second
part the trapping and the blood volume are removed from the
data and the method re-estimates the equilibrating components.
These two steps are repeated until a stabilization of the WRSS is
reached. For the presence of this iterative cycle in the correction
of the spectrum we have called this method Spectral Analysis
Iterative Filter (SAIF).
7.1.2 Details
In the previous paragraph we have introduced the idea on which
the SAIF algorithm is based. Now, let us explain the details of
the method. Firstly, the data were processed with the Cun-
ningham SA in order to provide the spectrum for the filtering
process. Then, after the selection of the cut-off interval, the
cycle of iteration for the correction of the spectrum is applied.
The procedure can be divided in the following points:
1. The double Turkheimer filter: The components inside
the cut-off interval are subtracted from the data and new
values of the trapping compartment and the fraction of vol-
ume occupied by the blood (Vb) are estimated (1st filtering);
2Because the Turkheimer SA is interesting principally in the trapping component esti-
mate, it does not require an accurate evaluation of the other components of the spectrum.
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2. The new estimation of the equilibrating components:
Using the same principle as the 1st filtering the new values
of trapping and blood contribution are subtracted from the
original data. From the results the components inside the
cut-off interval are re-estimated using a nonnegative esti-
mation algorithm (2nd filtering);
3. Stop Criterion: The difference between the WRSS before
and after the filter correction is calculated: if it is less than
0.1% the algorithm stops. Otherwise the algorithm restarts
from point 1.
In Figure 7.1 we illustrate the operative mechanism of the SAIF
(Details of the SAIF algorithm are in Appendix C). The role
of the cycle is fundamental: through this the algorithm we at-
tempt to strike a balance between the equilibrating components
and the limit components (the trapping and Vb) by eliminating
those components which are outside the cut-off interval.
The choice of WRSS variation as index for stop criterion is very
important in the SAIF. In fact, with this strategy we do not
need to define a priori the number of iterations, but the char-
acteristics of the analyzed data determine when the iterations
are stopped. In practice, with a mid level of noise in the data,
the number of iterations ranges from 1 to 50. In the case in
which all equilibrating components estimated from standard SA
are inside the cut-off interval, no additional iterations are made
by SAIF.
Like the SA Turkheimer method, the cut-off choice represents
the prior information about the data. This knowledge, used for
the algorithm to provide better estimates, greatly influences the
final spectrum, and therefore also the estimates of the variables
of interest. For these reasons it is very important to find an op-
timal value to apply in the algorithm. As with the Turkheimer
SA approach we used a simulation to find an optimal value for
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the cut-off interval; the same value was then applied to the mea-
sured data.
Figure 7.1: The SAIF. (A) The spectrum provided by Cunningham SA
method; (B) The choice of the cut-off interval on the evaluated spectrum;
(C) 1st filtering: The contributions of components inside the cut-off inter-
val are subtracted from the data and new values of the trapping and Vb are
estimated; (D) 2nd filtering: The contributions of the trapping and blood
volume are subtracted from the data and new values for the components in-
side the cut off interval are estimated. The iteration cycle is the repetition
of the last two points. The WRSS variation provides the stopping criterion.
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7.2 The simulation for the SAIF
Before applying the SAIF to acquired data we tested the quality
of the algorithm in simulation studies in order to understand its
behavior under different conditions. The approach that we used
was exactly the same as utilized for the SA with the Turkheimer
double filter (Section 6.3). The principal idea on which the sim-
ulations were based was to define a dataset as realistically as
possible, even though it is impossible to reproduce exactly all
the events that contribute to the acquired data.
As in the Turkheimer simulations, the same spectrum, the same
variables of interest, the same condition and the same perfor-
mance indices were used for the tests. We report the results
for SAIF simulations in different conditions in the following sec-
tions.
7.2.1 Different values for the cut-off interval
As we know from the simulation for the Turkheimer SA this
point is crucial for the application of the algorithm in measured
data. Our goal is, in fact, to select the cut-off interval that pro-
vides the lowest bias and the best distribution of the parameters
of interest. To determinate the best solution we used a discrete
approach in which we tested different values for the both the
endpoints of the cut-off interval. The values were chosen looking
for the sampling interval in order to define the slowest and the
fastest component detectable from the data. In Figures 7.2, 7.3
and 7.4, and in Figures 7.5, 7.6 and 7.7, we report the estimates
for λ and rCPS respectively for different choices of cut-off inter-
val endpoints. As we can see from the results and the graphs,
the optimal choice coincides with the narrowest cut-off interval
[0.03; 0.3]. A distribution of the components detected with the
optimal cut-off choice is reported in Figure 7.8. We can distin-
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guish very well the trapping the two equilibrating components
of the simulated spectrum. The fastest component is instead
due to the presence of the blood that the algorithm is not com-
pletely able to separate from true equilibrating components.
We have also tested the SAIF with values for the cut-off interval
that do not include the simulated components to understand
what happens. The results are better than expected: the al-
gorithm adapts the results to the range of the cut-off interval
(Figure 7.9).
Figure 7.2: λ estimates for the different values of cut-off intervals. The results
are means for the 1,000 simulated signals.
7.2.2 Different numbers of betas on the grid
We tested 3 grids with 50, 100 and 200 betas respectively but,
as with the Turkheimer method, there were no differences in
the means values of the estimates. The grids differ, however,
in the distributions of the components that they provide, in the
variance in the parameters of interest and in the processing time
that they required. We chose 100 as a good compromise between
computational time and precision.
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Figure 7.3: Map of λ bias for different cut-off interval choices.
Figure 7.4: Map of λ SD estimates for different cut-off interval choices.
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Figure 7.5: rCPS estimates for the different values of cut-off intervals. The
results are means for the 1,000 simulated signals.
Figure 7.6: Map of rCPS bias for different cut-off interval choices.
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Figure 7.7: Map of rCPS SD estimates for different cut-off interval choices.
Figure 7.8: Distribution of the spectral components with the optimal choice
of the cut-off interval. The simulated components are [α0 = 0.01 ; β0 = 0.00],
[α1 = 0.01 ; β1 = 0.05], [α2 = 0.04 ; β2 = 0.20] and Vb = 0.05.
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Figure 7.9: Distribution of the spectral components with bad choice of the
cut-off. In this case one of the equilibrating components (the slowest β =
0.05 min−1) is not included in the cut-off interval and the algorithm reacts
detecting in each simulation the slowest possible equilibrating component
located at β = 0.1 min−1.
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7.2.3 Different noise levels
In Figure 7.10 we report the estimates using a 100-betas grid and
the optimal choice for the cut-off interval. The results provide
acceptable bias for all noise levels (Equation 3.5) consistent with
those estimated for ROIs in the human brain (range N=0.15 to
N=1.0), and are indeed better than the ones provided with the
Turkheimer filter. We tried also a very high scale for variance
for the noise, N=15, to simulate noise which approaches to the
noise in voxel data, but the results were unsatisfactory (bias
> 100%). It is our opinion that to apply SAIF with high noise
levels something has to be changed, for example, introducing a
data pre-filtering in order to smooth the signals.
Figure 7.10: λ and rCPS estimates for different noise values. The results are
mean ± SD for the 1,000 simulated signals.
7.2.4 Considerations
Looking at the simulation results we find the following consid-
erations:
• The number of betas used influences more the computa-
tional cost than the distribution of detected components.
Although there is always the presence of very fast phantom
components, these are due to the underestimation of Vb and
not to the number of the betas in the grid. We obtained
identical results for 50, 100, 200 betas.
115
• At the Noise level typical of ROI data, biases are small
(< 1%) and precision reasonable (CV < 2%).
• The choice of cut-off interval is fundamental: the bias and
accuracy of the parameters estimates depend on the cut-off
choice. We found a set of cut-off values that provided high
accuracy and very low bias in the parameter estimates.
• The new method leads to a good fit with reasonable increase
of computational time (4-5 secs per estimation) compared
to the standard SA techniques.
Even though the results of the simulation with SAIF are good,
we must compare SAIF to the other SA algorithms in order to
understand which is the best SA approach for quantifying rCPS.
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7.3 The comparison among the SA algorithms
7.3.1 The comparison
To test the different capacity of SA for quantifying the variables
of interest in the leucine PET data, we used the same simulation
approach defined for the SAIF and the Turkheimer SA. 1,000
signals, generated from the same spectrum (Section 6.3), have
been tested, with the following 5 different SA techniques:
1. Cunningham SA (NFFG)
2. Cunningham SA with the beta grid truncated so the upper
and the lower bounds match the optimal cut-off interval for
SAIF (NFSG)
3. Turkheimer double filter SA (SF)
4. SAIF without doubling correction (RF)
5. SAIF with doubling correction (RFDC)
The reasons for why we applied methods 2 and 4 were differ-
ent. The NFSG was introduced to emphasize that truncating
the beta grid without filtering the data is not a sufficient for
obtaining good estimates. The RF, i.e. SAIF algorithm with-
out the doubling correction, was used instead to show that the
doubling correction has no influence on the estimates as we have
explained (Section 4.3). In Figure 7.11 we compare the different
fits of the simulated data. The weighted residual trends ob-
tained from the curves of Figure 7.11 with the simulated data
are reported in Figure 7.12. In Figure 7.13 and 7.14 we com-
pare the estimates of the variables of interest KPatlak, K1, Vb, λ
and rCPS. Figure 7.15 provides an idea of the variability of the
parameters among the 1000 simulation cases with the different
methods. In Figure 7.16 we report the bias of the estimated
variables.
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Figure 7.11: SA estimated curves compared with the simulated noise signals.
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Figure 7.12: Weighted residual trends from the different SA methods: (A)
Cunningham standard SA (NFFG); (B) Turkheimer SA (SF); (C) Cunning-
ham SA with truncated beta grid (NFSG); (D) SAIF methods (RF and
RFDC).
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Figure 7.13: Estimate comparisons between the 5 SA methods and the sim-
ulated variables.
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Figure 7.14: rCPS estimate comparisons between the 5 SA methods and the
simulated variables.
Figure 7.15: Coefficients of variation in all variables of interest for each the
SA methods examined.
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Figure 7.16: Bias in all variables of interest for each the SA methods exam-
ined.
7.3.2 The results of comparison
FIT
From Figure 7.11, we can see again the typical behavior of the
different SA methods. In particular, the poor fit of the data by
the Turkheimer SA method (blue line). The other approaches
provide good descriptions of the simulated data, even though
the SAIF-based method (RF and RFDC) are better than the
Cunningham-based methods (NFFG and NFSG).
Weighted residual trends
As we have explained in Chapter 4, this representation pro-
vides an idea about the goodness of the estimation method. All
SA techniques (Figure 7.12), except the Turkheimer approach,
present the expected random behavior in the residuals.
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The estimates for the variables of interest
In Figure 7.13 and 7.14 the orange bar (NFSH) and the green
bars (RF and RFDC) have a very good match with the simulated
values in all the variables of interest. In particular, for rCPS
quantification, these three methods provide the same estimates
with comparables errors. The yellow bar (NFFG) and the blue
bar (SF) do not have this characteristic, and for all the variables
they provide poor estimates. These methods correspond to the
Cunningham SA and the Turkheimer SA with double filter and
hence these results again confirm what we have reported in the
previous chapters.
Variability in the estimates: The Coefficient of Variation
Figure 7.15 reports a graphic representation of the precision that
the methods have in the examined variables. The worst results
correspond to the Cunningham SA (NFFG) and Turkheimer
method (SF). The best results are provided by the SAIF algo-
rithms (the green bars) which are significantly better that the
others. The orange bars related to the Cunningham SA with
a truncated beta grid (NFSF) has comparable values with the
SAIF for all variables except Kpatlak. This is a logical conse-
quence of the lack of a correction of the trapping component in
the Cunningham algorithm.
Bias in the estimates
Figure 7.16 represent the goodness of the estimates for the differ-
ent methods by comparing the bias. As we can see from the bar
graph, the Cunningham SA (NFFG) and Turkheimer SA (SF)
provide the most underestimated and overestimated results, re-
spectively. The others methods have low bias although the SAIF
methods (RF and RFDC) are visibly better than the Cunning-
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ham SA method define with a truncated beta grid (NFSG) for
KPatlak, λ and rCPS.
7.3.3 FINAL CONSIDERATIONS FROMTHE COM-
PARISON
From the results that we conclude that the SAIF correction is
the best of the five SA methods analyzed for the quantification
of rCPS in leucine PET data. In fact, it is characterized by
the lowest bias, the best fit of the simulated data, a reasonable
residual trend and a good accuracy on the parameter estima-
tion. The simulation studies also demonstrate that there are
not any notable different in the estimates provided by the SAIF
with and without the doubling correction. This means that our
approach for the elimination of the double components works in
the way that we wanted because it resolves the problem of the
doubling without compromising the quality of the results.
Interesting are the results provided with the Cunningham SA
method defined on a truncated grid of betas (NFSG). The re-
sults are considerably better than the standard Cunningham
method (NFFG) but not as good as the SAIF (RF, RFDC).
This suggests that the beta grid choice is very important for de-
termining the quality of the results, but it is not the only feature
to take into account.
The most important problem of SA is related to the absence of
a criterion based on the data for the choice of cut-off interval. In
the next section, we present the method that we used to set-up
the SAIF algorithm for the analysis of our acquired data.
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7.4 The choice of cut-off interval
The lack of a data-driven criterion for the choice of the cut-off
interval could be an important limitation for the SAIF utiliza-
tion. The method, as we have explained, consists of defining a
dataset of simulated signals very close to the measured data, try-
ing different cut-off values in order to decide the best solution,
and finally applying the selected cut-off interval to the acquired
data. But this strategy is dependent on having realistic knowl-
edge of the kinetics of the measured data. As the underlying
kinetics are not known we have had to rely on estimates of the
kinetic parameters provided by other analysis methods.
To define a more data-driven method we considered whether the
SD values of estimated parameters could help to make a decision
on the optimal cut-off interval. First, however we had to solve
the problem of finding a good method for SD evaluation. We
know that the inverse of Jacobian Information matrix provides
a lower bound for the variance of the matrix (Section 4.3). For
the estimation of SD we compared, in a bootstrap simulation,
three different approaches:
• SD “true value”estimated from the variables of interest dis-
tributions;
• Linear Approach3: Jacobian inversion in SA linear model;
• Non Linear Approach4: Jacobian inversion in SA non linear
model (betas included);
The simulation was organized in this way: we defined a noisy
TAC signal, and we estimated the parameters of interest with
3The linear approach refers to the SA model (Section 4.3) in which only the αs and Vb
are the parameters of the model and the βs are fixed.
4The non linear approach refers to the same model as the linear approach but in this
case βs are not considered fixed but variables of the models. In this way the equation
associated with the model is a non linear function of the parameters (αs, βs, Vb).
125
SAIF as usual. Then, using the weighted residual difference be-
tween the estimated curve and the simulated data, we defined
1,000 realization of the same signal with a bootstrap5 technique.
Each signal was processed with SAIF and the SD with the lin-
ear and non linear approach was estimated. At the end of this
elaboration we had three groups of values: 1000 estimated vari-
ables of interest, 1000 SD values from the linear approach and
1000 SD values from the non linear approach. The SD calcu-
lated from the distribution of the estimates represented what
we called “the true value”and the averages from the other two
groups were the SD with linear and non linear approach, respec-
tively. In Figure 7.17 we report the comparison of these three
groups for all the variables of interest. As we can see the lin-
ear approach underestimates the true values, and the non linear
approach overestimates them to a considerably higher degree.
In light of these results, we decided that the best way to define
the precision for the estimates is through the inverse Jacobian
matrix based on the linear model.
Even though this discussion about the best method to estimate
SD is interesting, it was not found to be helpful for the problem
of the cut-off interval choice as elaborated below. In fact, the
optimal choice has to be a compromise between least bias and
best precision for the parameter estimates. These two factors
work in an opposite way, so if we consider only the SD for the
cut off we will produce estimates with very good precision but
very large bias.
5In statistics, bootstrapping is a modern, computer-intensive, general purpose approach
to statistical inference, falling within a broader class of resampling methods. Bootstrapping
is the practice of estimating properties of an estimator (such as its variance) by measuring
those properties when sampling from an approximating distribution. One standard choice
for an approximating distribution is the empirical distribution of the observed data. In the
case where a set of observations can be assumed to be from an independent and identically
distributed population, this can be implemented by constructing a number of resamples of
the observed dataset (and of equal size to the observed dataset), each of which is obtained
by random sampling with replacement from the original dataset [9].
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Let us to consider for a moment the Bayesian estimation method.
The results depend on a regularization parameter (γ) that weights
a priori and a posteriori information on the variables that we
want to estimate. It is not our interest now to explain how
this algorithm works, but what is important is the role of γ.
The choice of this regularization parameter is affected, as is the
choice of the cut-off interval, by the problem of finding the op-
timal value that is the best trade-off between prior assumptions
and data analysis. If γ is unbalanced towards one of these two
sides, the estimates have too much bias or too much variability,
respectively. The equation to determinate the best choice of γ
takes into account the statistical distribution of the error in the
data and the prior information about the data. If we consider
the cut-off interval as the correspondent of γ in the SA, the cri-
terion for its choice has to be defined in the same way. Thus
we reasoned that we could not use SD for defining a data-driven
choice of cut-off interval. For the moment the approach based
on the simulation is the only method that we have for choosing
the cut-off interval.
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Figure 7.17: Different methods for the estimation of precision of the variables
of interest. Instead of the SD the CV = SD/(simulated value) is reported
here in order to have the same normalized view of all the parameters.
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7.5 Final consideration about the SAIF
The Spectral Analysis Iterative Filtering, that we have defined
and tested in simulation studies, seems to be the best Spec-
tral Analysis algorithm for the quantification of rCPS in leucine
PET data. Even though these preliminary results can not be
completely sufficient to establish if SAIF is or is not a valid
quantification method, we can conclude that the innovative fea-
tures of the method, in particular the presence of the iterative
cycle filter, improve the estimate quality compared to the other
SA techniques.
The reason for this is due to a better estimation of the spec-
trum that the SAIF provides from the data. If we consider
the spectrum estimated with the three principal SA methods
(Cunningham SA, Turkheimer SA, SAIF) (Figure 7.18) we can
see that the new algorithm gives a better approximation of the
simulated spectrum. In particular, it conserves multiple equi-
librating compartments that are due to the tissue heterogene-
ity, which are absent in Turkheimer SA or not consistent with
the data assumptions6 in Cunningham SA. We report a graphic
representation of the spectrum in Figure 7.19. It is interesting
to see that the lowest simulated equilibrating component is de-
tected only by the SAIF even though the fastest one is better
represented by the Cunningham and Turkheimer method. Also
the sum of the estimated αs, which is equivalent to the parame-
ter K∗1 (Equation 6.15), is better estimated by the SAIF method
compared to the other methods.
Thus we can se that SAIF produces better estimates of the spec-
trum that Turkheimer SA or Cunningham SA methods. It is,
therefore, not surprising that it provided better estimates of the
6In Cunningham SA the fastest component is located at β = 1.26 min−1. This value is
too high compared to the fastest detectable component in the leucine PET data and for
this reason it is not realistic.
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macro parameters of the system, i.e. rCPS and λ, as shown in
the previous section. The SAIF presents also some disadvan-
Figure 7.18: The spectra provided with SAIF, Turkheimer SA and Cunning-
ham SA from a simulated signal.
Figure 7.19: Three spectra estimated with Cunningham SA, Turkheimer SA
and SAIF, respectively. The estimates are compared with the simulated
value.
tages. The most important is related at the choice of the Cut-off
interval that conditions directly the quality of the estimates. A
data-driven criterion is lacking but for our data we have found
a method to define it that provides useful results. The SAIF,
as the other spectral techniques, is also characterized by a low
estimate precision compared to the compartmental-model based
method. This is most probably due to the high number of pa-
rameters that SA uses, and thus it is unavoidable when we apply
130
the method.
To finally evaluate the qualities of SAIF we tested it on mea-
sured data. The estimates were compared with the results of
the other two methods previously used to analyze leucine PET
data: using NLLS to estimate parameters of the homogenous
tissue kinetic model at the ROI level [2] and using a Basis Func-
tion method to estimate parameters of the homogenous tissue
kinetic model at voxel level [35]. The latter method is summa-




The Basis Function Method
(BFM)
8.1 A method for rCPS estimation at voxel
level
In this section we describe the BFM and the way in which we
used it to estimate rCPS at ROI level.
8.1.1 Introduction to the BFM
As we have seen (Section 3.4), the NLLS applied to HOM for the
rCPS estimation from the leucine PET data is affected from the
incapacity of the kinetic model to take in account the hetero-
geneity in the tissues. The application of the NLLS to the HET,
instead, could represent better the mixture of the tissues present
in the ROI but it has characterized by convergence problems.
Additionally NLLS algorithms have a high cost that prevents
their being used at voxel level. It is for this particular reason
that BFM has been developed [35].
BFM is a very fast method defined to estimate the variables of
interest, which, due to its speed, is practical to apply at voxel
level. This approach is based on the same homogenous tissue
kinetic model defined for the leucine (Equations 3.1, 3.2), but it
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differs to the NLLS-HOM method in the algorithm that it uses
for rate constant estimation. It is important to emphasize the
differences between the NLLS-HOM and BFM because there are
three aspects that interact:
1. the estimation algorithm;
2. the kinetic model used to represent the data;
3. the level to which the method is applied (ROI or voxels).
In light of these aspects the BFM can be also elaborated as
BFM-HOM-VOXEL. This means that the Basis Function Me-
thod algorithm is applied with the HOM model to estimate the
variables of interest from the voxel TACs. The NLLS-HOM is
different. It applies a non linear estimation algorithm to esti-
mate rCPS at ROI level through a homogenous kinetic model.
So from these definitions it is easy to notice that BFM and
NLLS-HOM differ for the estimation algorithm that they used
and for the TACs to which they are applied.
From BFM-HOM-VOXEL it is also possible to calculate rCPS
and at ROI level simply by averaging the results of the estimates
among all voxels within the ROI. This approach is substantially
different than applying BFM directly to estimate parameters
from ROI time-activity curves because tissue heterogeneity is
likely to be far greater within a ROI than within a voxel. Start-
ing with BFM estimates at the voxel level and averaging to ob-
tain values at the ROI level is an alternative approach to NLLS
and SA for estimating rCPS in the different regions of the brain.
8.1.2 Fundamentals
To understand the BFM method let us to consider again the
measurement equation associated with the HOM (Equation 3.2).
This equation relates the total concentration of 11C (C∗T ) in a
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generic voxel at time t to the measured [11C]leucine concentra-
tion in plasma (C∗p), total
11C in whole blood (C∗b ), and
11CO2
concentration in tissue (VDC
∗
c ) as follows:
























β = k2 + k3 + k4 (8.2)
Equation 8.1 can also be written as:













b (t)− VDC∗c (t)] + VDC∗c (t)
(8.3)
with
Θ1 = (1− Vb)
(
K1(k2 + k3)
k2 + k3 + k4
)
(8.4)
Θ2 = (1− Vb)
(
K1k4
k2 + k3 + k4
)
(8.5)
Θ3 = Vb (8.6)
If the value of β were known, Equation 8.3 would linear in the
parameter vector Θ = [Θ1,Θ2,Θ3] which could be quickly esti-
mation using the standard linear estimation method, i.e. the
Weighted Linear Least Squares (WLLS). The WLLS, unlike
NLLS, doesn’t require an iterative algorithm for the solution,
but utilizes a direct formulation that reduces drastically the
computational time for the estimation. The idea of the BFM
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is to define a grid of values for β in the physiological range,
β1, β2, ..., βm, solve for each of them the corresponding linear
problem expressed by Equation 8.3, and then select the value





3] be the estimated parameter vector at β = β
∗.
Equations 8.4-8.6 can then be solved to yield the final values of
























Unfortunately, Equations 8.7 - 8.10 may provide one or more
negative parameter estimates for a given voxel, while all rate
constants and Vb should be nonnegative. The introduction in
the estimation algorithm of a non-negative constraint would
increase substantially the computational time, and processing
speed, which is the most important feature of BFM, would be
lost. Rather than do this or exclude these voxels from the
analysis, which would likely create problems when considering
ROI/voxel correlation, doctor Giampaolo Tomasi, of Yale Uni-
versity, developed a strategy (Appendix D) to reanalyze each
voxel that had one or more negative parameters after the initial
BFM estimate. Only if non-negative parameter estimates could
not be achieved after reanalysis was a voxel discarded from fur-
ther considerations. For our dataset, 100 values equally spaced
between 0.0001 min−1 and 0.5 min−1 were used as the predefined
1It is not necessary to use other kind of comparison indexes as the AIC to chose β∗
with the model does not change. In this way the information of WRSS reflects exactly
the information provided by AIC.
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grid for β, as this widely covers the range of physiological values
expected for k2 + k3 + k4.
The choice of the number of βs in the fixed grid is an important
parameter for the BFM algorithm. In fact, if the grid was very
density populated of beta, the estimate result could be more
accurate but in the same time the computational time would in-
crease considerably. The determination of the number of betas
is very similar problem to the decision of the length of the com-
ponent grid in SA. The choice of 100 βs is a good compromise
between the computational efficiency and estimate precision.
8.1.3 BFM for estimation at ROI level
Even though the BFM is based on the homogenous kinetic model
in the same way as NLLS-HOM technique, the estimates pro-
vided by the two methods for the ROI level are different. The
reasons of this behavior are due to the different approaches that
BFM applied to the voxel level and NLLS applied to the ROI
level use to calculate the variables of interest for the different
regions. In Figure 8.1 a representation of the different paths
used by the methods is shown. The NLLS-HOM method fol-
lows the direction indicated from the red arrows. Before the
estimation, voxel time-activity curves are averaged in a single
signal. This signal represents the time-activity curve associ-
ated with the ROI. From this the variables of interests are es-
timated through the NLLS based on the homogenous tissue ki-
netic model.
The BFM, instead, uses the opposite approach (violet line).
Firstly the estimates of the variables of interest for all the vox-
els are provided using for each time-activity curve the BFM ap-
proach. Secondly by averaging the results the estimates at ROI
level are calculated. Even though the red and the violet paths
of Figure 8.1 both arrive a ROI-level estimates, the methods
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Figure 8.1: The estimation paths in NLLS-HOM-ROI (red line) and BFM-
HOM-VOXEL (violet line).
that they represent are not equivalent. In fact, although BFM
and NLLS use the same model we expect different results due
to the heterogeneity contained inside the signals in which they
are applied. To understand this let us to focus the attention on
the different volumes that a voxel and a ROI refer to. Recon-
structed voxels for scans conducted on the HRRT have a volume
of ∼1.8 mm3. A ROI instead is generally made up of thousands
of these elements and so the volume that it represents is larger
by several orders of magnitude. In accordance with this feature,
the mixture of tissues that a voxel contains cannot be compare
with the variability present in a ROI. If the heterogeneity is so
different, it is evident that the descriptions of the systems, at
the voxel and ROI levels, provided by the homogenous kinetic
model can not be the same. Consequently we expect that the
HOM works better where the system is more homogenous, i.e.
at voxel level. From these considerations the BFM applied at
the voxel level seems to be a better instrument to estimate the
variables of interest. The fit of the TACs elaborated from the
results of the estimations in measured data could suggest some-
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thing about this hypothesis.
All these considerations are based on one of the two differences
that BFM and NLLS-HOM have, i.e. the kind of TAC to which
the methods are applied. The other difference, regarding the
algorithms that BFM and NLLS used for the estimations, does
not condition the estimates but only the speed of the algorithm
[35]. In fact, simulation experiments showed that NLLS and
the linear approach with the fixed grid of betas of BFM can be
considered equivalent [35].
8.1.4 Application of BFM in simulation and real data
Before applying the method to the measured data, BFM was
tested and compared with NLLS in simulation experiments at
voxel and ROI level. The simulation [35] shows a good agree-
ment when BFM and NLLS are applied to the voxel TACs. The
results at ROI level, calculated by the two methods described
above, are instead very different. In particular, what is different
is the bias of the methods (Chapter 9). For the NLLS applied at
the ROI level the range is 15-20% whereas the BFM bias range
is 0-7%.
After these tests on simulated data, BFM was applied the ac-
quired data of our subjects [35]. The results are reported in the
next chapter where they are compared to the others provided
by NLLS at the ROI level and spectral analysis.
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Figure 8.2: BFM estimates at voxel level. From these results the method can
provide also the estimates at ROI level by averaging the parameters values








In this chapter we report the results for the rCPS estimation at
ROI level using all the available quantification methods that we
have discussed in the previous sections: the NLLS based on the
homogenous tissue kinetic model and applied at the ROI level
(Chapter 3), the Basis Function Method based on the homoge-
nous tissue kinetic model and applied to voxel level (Chapter 8),
and our Spectral Analysis algorithm SAIF (Chapter 7) applied
to the ROI level.
In Figure 9.1 the rCPS averages among the 9 subjects are
shown for all the regions of interest. The SD represents the
intersubject variability. From these results we can see that BFM
and SAIF are in good agreement, although SAIF values tend
to be slightly lower. Values for NLLS-HOM are considerably
higher. This is consistent with what we know about the bias
of the methods. Recently studies [35] demonstrated that NLLS
applied to HOM at the ROI level overestimates the rCPS by
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about 15-20%. The BFM instead, tends to underestimate the
data, but, the bias is lower (at most 5%), and for some ROIs,
such as the white matter, it is very close to zero. Our simulation
studies show that the SIAF has a behavior similar to the BFM.
In fact, SAIF underestimates the rCPS, with an average value
of 2-3%.
From Figure 9.1 we can also observe different SD between
the methods. The SAIF has the highest values, BFM that is
characterized the lowest. This is consistent with the different
accuracy of the algorithms. SAIF has larger number of param-
eters and thus the larger standard errors in the estimates: this
may influence the inter-subject variability.
Consider now the bar graph of Figure 9.2. The image provides
a graphic representation of rCPS estimated with the different
methods. We can see again the same considerations as in Fig-
ure 9.1, i.e. that the NLLS-HOM-ROI estimates are higher than
the other two methods, that BFM and SAIF are more similar to
each other and that the SAIF provides the highest inter-subject
variability among all the analyzed methods. In Figure 9.3 and
9.4 we report the estimates of λ. The BFM and SAIF meth-
ods are in good agreement, but NLLS-HOM-ROI provides lower
values. The SD is very similar for all three methods. In Figure
9.5 and 9.6 we report the estimates and the bar graphs for the
K1 (mL/g/min). As with λ the BFM-HOM-VOXEL and SAIF-
ROI are similar but the NLLS-HOM-ROI estimates are visibly
lower. The SD is the same in all the methods. In Figure 9.7 and
9.8 we report the Vb estimates. NLLS-HOM-ROI provides visi-
bly higher estimates than the other two methods. In summary
we can see in estimates of all the parameters that BFM-HOM-
VOXEL and SAIF-ROI provide results in good agreement with
each other, but differ from those provided by NLLS-HOM-ROI.
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Figure 9.1: rates of cerebral protein synthesis (nmol/g/min) estimated with
different algorithms in different regions of interest. The values are the mean
± SD for 9 subjects.
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Figure 9.2: rates of cerebral protein synthesis (nmol/g/min) bar graph. The
results are estimated with different algorithms in different regions of interest.
The values are the mean for 9 subjects. The lines represent the SD.
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Figure 9.3: λ estimated with different algorithms in different regions of in-
terest. The values are the mean ± SD for 9 subjects.
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Figure 9.4: λ bar graph. The results are estimated with different algorithms
in different regions of interest. The values are the mean for 9 subjects. The
lines represent the SD
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Figure 9.5: K1 estimated with different algorithms in different regions of
interest. The values are the mean ± SD for 9 subjects.
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Figure 9.6: K1 bar graph. The results are estimated with different algorithms
in different regions of interest. The values are the mean for 9 subjects. The
lines represent the SD.
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Figure 9.7: Vb estimated with different algorithms in different regions of
interest. The values are the mean ± SD for 9 subjects.
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Figure 9.8: Vb bar graph. The results are estimated with different algorithms
in different regions of interest. The values are the mean for 9 subjects. The




The application of the NLLS based on the homogenous kinetic
tissue model (HOM) to the leucine PET data at ROI level is not
completely adequate for quantifying the rCPS and the other
variables of interest. This fact is the consequence of the fact
that HOM does not represent the mixture of tissues which are
present in the data due the limited spatial resolution of the
PET tomograph. The tissue heterogeneity that the HOM, by
definition does not take into account influences the fit of the
estimated-model curves with the data and the quality of esti-
mates of the variables of interest. In fact, as previous applica-
tion of the method have shown ([2];[35]) the typical trend of the
HOM model-estimated curve underestimates and overestimates
the data measures at the beginning and at the end of the data
acquisition interval, respectively. The model specification error
results in bias of the estimates provided by the NLLS-HOM-
ROI: -20 to -30% for k2 + k3, -8% for λ and +15 to +20% for
rCPS [35]. In light of these unsatisfactory values more accu-
rate approaches for the rCPS quantification at ROI level are
required.
A valid alternative to the NLLS-HOM-ROI is Spectral Analysis
(SA). Based on a generic compartmental model, SA can be ap-
plied to heterogeneous as well as homogeneous tissues without
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any prior assumptions concerning the number of tissue compart-
ments. Firstly we used SA to choose the best compartmental
model for the representation of the TACs associated with the
different ROIs. Using an approach based on fixed SA models,
i.e. fixing a priori different numbers of equilibrating components
(with or without a trapping component) in different SA models,
we determined the degree of heterogeneity necessary to explain
the leucine PET data. From the Akaike Information Criterion
the model with two equilibrating components and one trapping
component was selected as the best. This SA model is consistent
with the heterogeneous kinetic tissue model (HET) defined for
the analysis of the leucine PET data [35]. This model, however,
was not useful for analysis of measured data because the high
number of parameters in the model caused convergence prob-
lems in the estimation process.
To overcome this limitation we applied the SA technique for
quantifying the parameters of interest from the leucine PET
data at ROI level. The traditional SA approaches, the Cunning-
ham SA and the Turkheimer SA were tested and then applied
to the measured data. The first method showed an excellent fit
(WRSS < 3) of the data, but nonphysiological estimates of the
variables of interest. The second, instead, presented a fit typical
of the HOM model applied to ROI data and nonphysiological λ
and rCPS estimates. The reason for the poor estimates of the
variables of interest is related to the incapacity of the methods
to provide a correct estimation of the spectra. The Cunningham
SA method does not estimate the trapping component and the
blood volume correctly. The Turkheimer SA technique, instead,
is affected by problems with the slowest equilibrating compo-
nents. These components are influenced by several of effects:
noise in the PET data, distortion in the arterial signals, shifting
of the trapping component, and the presence of real equilibrat-
ing components with slow kinetics.
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Because these SA methods did not consistently produce reliable
estimates when applied to L-[1−11C]leucine data, we developed
a new SA iterative filtering (SAIF) method to take into account
all these facets of the rCPS estimation problem.
SAIF uses prior information concerning irreversibility of trap-
ping of the tracer as well as components that cannot be distin-
guished from blood. This information determinates the value
of a cut-off interval that the SAIF uses to select the range of
the equilibrating components distinguishable in the data to be
analyzed. A data-driven criterion to determinate the value of
the cut-off is, however, missing. We used simulation-based ap-
proach for its choice.
Comparing SAIF with standard SA methods we observed that
our method yielded the best fit, the lowest bias (< 2%) and the
lowest CV (∼ 6%) in rCPS. In measured data, rCPS estimated
with SAIF agreed with the average of rCPS values estimated by
using HOM at the voxel level, but differed substantially from
ROI-based rCPS estimated by HOM. This is consistent with
the presence of a greater degree of tissue heterogeneity in the
ROI, compared to individual voxels, that is not accounted for
with the homogeneous tissue kinetic model. In most regions
CVs with SAIF were somewhat higher than when a fixed ki-
netic model was used, probably due to the increased number of
parameters estimated with SAIF.
Unlike the HOM, SAIF accounts for tissue heterogeneity and
thus it was found to be a useful and robust method for estimat-





All the algorithms for the parameter estimation used in this
work, like the NLLS for the HOM (Section 3.1), the WLLS for
the BFM (Section 8.1) or the lsqnonneg.m for SA (Section 7.1),
utilize for their processing the same weighted data approach
in which the weight of a measure is inversely proportional to






where Wi and SDi are the weight and the standard deviation of
the i-data point, respectively.
With this formulation the problem of how to weight the data
becomes the problem of how represent the error in the measured
data. To resolve the problem we assumed that the measured
activity follows Poisson statistics [42]. If we define the following
variables as
• Xi= total counts Frame i (not decay-corrected)
• Yi= count rate Frame i (not decay-corrected)
• Zi= count rate Frame i (decay-corrected)
• ∆ti= Length Frame i
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• ti= Midscan time, Frame i
• K= decay constant 11C = ln(2)/20.38 min
From the Poisson equation we know that





























From the expression for the decay correction we know that Zi =
eK·tiYi and in the same way Yi = e−K·tiZi.













Equation A.6 is exactly the same, with some difference in nota-
tion, to that reported in (3.2), namely







where ti is the midpoint of the i-th frame, γ is the decay constant
for 11C, ∆ti is the length of Frame i, N is a proportionality
coefficient reflecting the noise level in the data and CT (ti) is the
total activity registered by the scanner.
In PET N is a priori unknown, but its value is not necessary
for the estimation because it is only a scale factor. N is only
required to calculate the precision of estimated parameters and
for this reason it is estimated a posteriori [6].
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Appendix B
The relationship between rCPS
and the HOM parameters







is necessary to consider the equation of the HOM model for the
unlabelled leucine{
dCE
dt = K1Cp(t)− (k2 + k3 + k4)CE(t) + k5P (t)
dP
dt = k4CE(t)− k5P (t)
(B.2)
where CE is free unlabelled leucine in the tissue, P is the unla-
belled leucine incorporated into protein in the tissue, Cp is the
free leucine in the plasma and K1, k2, k3, k4 and k5 are the rate
constants of the homogeneous kinetic model for the unlabelled
leucine (3.2).
One of the hypotheses of this model is that the leucine is in






In light of this B.2 can be written as{
K1Cp(t)− (k2 + k3 + k4)CE(t)k5P (t) = 0
k4CE(t)− k5P (t) = 0 (B.4)
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For its definition rCPS is the rate of proteins synthesis so it cor-
responds to the flux of leucine that comes from the free leucine
compartment CE to the Protein compartment
rCPS = k4CE (B.5)



















That is exactly Equation B.1, i.e. the relationship between rCPS




In this section we report the details of the Spectral Analysis It-
erative Filter algorithm
C.1 Algorithm - The MAIN PROGRAM
• Set up of the SA model variables: We initialized the following
variables:
⇒ Number of components (default: N=100)
⇒ Kind of grid (default: DiStefano distribution)
⇒ Choice of the Cut-off interval (default: Optimal value
selected from simulation)
For subject=1 to 9
• Load the arterial signals of the subject;
• Correction of the blood signal from the pre-determined tracer
arrival delay;
• Set up of the SA required data:
⇒ Load of the ROI Leucine PET data (OriginalPET-
Data);
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⇒ Construction of Transfer Matrix (Figure C.1) through
the convolutions between the betas of the grid and the
plasma samples;
• For ROI=1 to NumberOfROI
⇒ Evaluation of the data weights
⇒ Reduction of the Transfer Matrix to the PET sampling
grid
⇒ Spectral Analysis Iterative Filter
⇒ Conversion of the spectrum into the variables of inter-
est
• End ROI cycle
End subject cycle.
Legend:
N number of betas in the grid
NumberOfROI number of ROI examined for each subject
C.2 Algorithm - The SAIF
• Cunningham SA: The first Spectrum S (where S is the
vector of αi and Vb) is estimated applying the lsqnonneg.m
to the Transfer Matrix and the OriginalPETData;
• WRSS is calculated from the model-estimated curve and
the OriginalPETData;
• Set Up for the iterative filter: From the Transfer Matrix
we define the External component matrix Me using the
columns that refer to the trapping component and the blood
component, and the Internal component matrix Mi using
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the part of the Transfer Matrix related to equilibrating com-
ponents inside the cut-off interval (Figure C.1);
• 1st filtering:
⇒ We defined ModifiedPETData1 = OriginalPETData -
Contributions of Mi (Calculated from S)
⇒ New values of the trapping component and Vb are esti-
mated applying lsqnonneg.m to the Me and Modified-
PETData1. S is updated with the new estimates;
• 2nd filtering:
⇒ Define ModifiedPETData2 = OriginalPETData - Con-
tributions of Me (Calculated from S)
⇒ New values of equilibrating components are estimated
applying lsqnonneg.m to the Mi and ModifiedPET-
Data2. S is updated with the new estimates;
• A new value for WRSS is calculated after the two filtering
steps. If the difference with the old value is more than 0.1%
the algorithm restarts from the 1st filtering. If not, the
algorithm exits from the correction cycle and last version
of the spectrum S defines the final estimated spectrum S∗;
• Correction for the doubling effect in S∗ by the Equation
(4.3);
• Estimation of the CV for the detected components in S∗
and Vb through the inverse of the Jacobian Matrix.
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Figure C.1: The SAIF Matrices. The scheme shows how from the Transfer
Matrix we defined the Internal and External component Matrixes, Mi and
Me, respectively, necessary for the iterative filtering cycle.
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Appendix D
The BFM algorithm for the
non-negativity correction
This is the algorithm used for the negativity correction of the
parameters estimated with BFM [35]. The rate constants and
the equations refer to the ones used to describe BFM (Equations
8.1-8.10). Defined by Giampaolo Tomasi of Yale University the
method yields nonnegative estimates without using a non linear
estimation approach. However, this algorithm doesn’t work for
all the voxels because some of them, even though only a very
small fraction (generally < 1%), cannot be corrected. Rather
than apply a costly constrained NLLS approach, these voxels






3] be the estimated parameter vector at β =
β∗. Calculate K1, k2+ k3, k4 and Vb from Equations (Equations
8.7-8.10).
If K1 ≤ 0 or k2 + k3 ≤ 0:
Discard voxel.
Else if Vb < 0:





Calculate K1, k2 + k3, k4 from Eqs (8.7-8.9) .
If k4 < 0:
Set Θ∗2 = Θ
∗
3 = 0 in Eq (8.3) and re-estimate Θ
∗=[Θ∗1]
Set k4 = 0 and calculate K1, k2 + k3 from Eqs (8.7-8.8).
If K1 ≤ 0 or k2+k3 ≤ 0 discard voxel; otherwise retain voxel.
Else if k4 < 0:




Set k4 = 0 and calculate K1, k2 + k3, Vb from Eqs (8.7, 8.8,
8.10).
If Vb < 0:
Set Θ∗2 = Θ
∗
3 = 0 in Eq 8.3 and re-estimate Θ
∗=[Θ∗1]
Set Vb = 0 and calculate K1, k2 + k3 from Eqs (8.7, 8.8).






[1] A. Bertoldo, P. Vicini, G. Sambuceti, A. A. Lammertsma,
O. Parodi, and C. Cobelli. Evaluation of compartmental
and spectral analysis models of [18F]FDG kinetics for heart
and brain studies with PET. IEEE Trans Biomed Eng,
45(12):1429–48, 1998.
[2] S. Bishu, K. C. Schmidt, T. Burlin, M. Channing, S. Co-
nant, T. Huang, Z. H. Liu, M. Qin, A. Unterman, Z. Xia,
A. Zametkin, P. Herscovitch, and C. B. Smith. Regional
rates of cerebral protein synthesis measured with L-[1-
11C]leucine and PET in conscious, young adult men: normal
values, variability, and reproducibility. J Cereb Blood Flow
Metab, 28(8):1502–13, 2008.
[3] S. Bishu, KC Schmidt, and CB Smith. Propofol anesthesia
does not alter the regional rates of cerebral protein synthesis
measured with L-[1-11C]leucine and PET in healthy male
subjects. J Cereb Blood Flow Metab, 2009.
[4] D. J. Brooks, A. A. Lammertsma, R. P. Beaney, K. L. Leen-
ders, P. D. Buckingham, J. Marshall, and T. Jones. Mea-
surement of regional cerebral pH in human subjects using
continuous inhalation of 11CO2 and positron emission to-
mography. J Cereb Blood Flow Metab, 4(3):458–65, 1984.
[5] R. B. Buxton, N. M. Alpert, V. Babikian, S. Weise, J. A.
Correia, and R. H. Ackerman. Evaluation of the 11CO2
165
positron emission tomographic method for measuring brain
pH. I. pH changes measured in states of altered PCO2. J
Cereb Blood Flow Metab, 7(6):709–19, 1987.
[6] R.E. Carson, C. Cobelli, and L. Filkestein. The Mathemat-
ical Modeling of Metabolic and Endocrine Systems. Wiley,
New York, 1993.
[7] R. C. Collins, N. Nandi, C. B. Smith, and L. Sokoloff. Focal
seizures inhibit brain protein synthesis. Trans Am Neurol
Assoc, 105:43–6, 1980.
[8] V. J. Cunningham and T. Jones. Spectral analysis of dy-
namic PET studies. J Cereb Blood Flow Metab, 13(1):15–23,
1993.
[9] B Efron. Bootstrap methods: another look at the jackknife.
Ann. Statistic, 1979.
[10] Carson R et. al. Design of a motion-compensation OSEM
list-mode algorithm for resolution-recovery reconstruction
for the HRRT, 2003.
[11] Johnson CA et. al. Software architetture of the MOLAR-
HRRT recostruction engine. IEEE Trans. Nucl Sci., 2004.
[12] B. Fischer and J. Modersitzki. Intensity-based image regis-
tration with a guaranteed one-to-one point match. Methods
Inf Med, 2004.
[13] Akaike Hirotugu. On a decision procedure for system iden-
tification. Engineering approach to computer control, 1971.
[14] H. Hsu, V.R. Young, and A.J. Fischman. Measurement of
muscle protein synthesis by positron emission tomography
with L-[methyl-11C]methionine. Proc Natl Acad Sci USA,
1996.
166
[15] H. Iida, S. Higano, N. Tomura, F. Shishido, I. Kanno,
S. Miura, M. Murakami, K. Takahashi, H. Sasaki, and
K. Uemura. Evaluation of regional differences of tracer ap-
pearance time in cerebral tissues using [15O] water and dy-
namic positron emission tomography. J Cereb Blood Flow
Metab, 8(2):285–8, 1988.
[16] M. C. Ingvar, P. Maeder, L. Sokoloff, and C. B. Smith.
Effects of ageing on local rates of cerebral protein synthesis
in sprague-dawley rats. Brain, 108 ( Pt 1):155–70, 1985.
[17] A. Lajtha, L. Latzkovits, and J. Toth. Comparison of
turnover rates of proteins of the brain, liver and kidney in
mouse in vivo following long term labeling. Biochim Bio-
phys Acta, 425(4):511–20, 1976.
[18] E. M. Landaw and 3rd DiStefano, J. J. Multiexponential,
multicompartmental, and noncompartmental modeling. II.
data analysis and statistical considerations. Am J Physiol,
246(5 Pt 2):R665–77, 1984.
[19] K. Murase. Spectral analysis: principle and clinical appli-
cations. Ann Nucl Med, 17(6):427–34, 2003.
[20] K. Murase, T. Tsuda, T. Mochizuki, and J. Ikezoe. Hep-
atic extraction fraction of hepatobiliary radiopharmaceuti-
cals measured using spectral analysis. Nucl Med Commun,
20(11):1041–5, 1999.
[21] K. Murase, T. Tsuda, T. Mochizuki, S. Tanada, and J. Ike-
zoe. Spectral analysis applied to hepatobiliary dynamic
scintigraphy with 99Tcm-N-pyridoxyl-5-methyltryptophan.
Nucl Med Commun, 18(11):1049–56, 1997.
[22] H. Nakanishi, Y. Sun, R. K. Nakamura, K. Mori, M. Ito,
S. Suda, H. Namba, F. I. Storch, T. P. Dang, W. Mendelson,
167
M. Mishkin, C. Kennedy, J. C. Gillin, C. B. Smith, and
L. Sokoloff. Positive correlations between cerebral protein
synthesis rates and deep sleep in macaca mulatta. Eur J
Neurosci, 9(2):271–9, 1997.
[23] PV. Nguyen, T. Abel, and E.R. Kandel. Requirement of a
critical period of transcription for induction of a late phase
of LTP. Science, 1994.
[24] C.S. Patlak and R.G. Blasberg. Graphical evaluation o of
blood-to-brain transfer constants from multiple-time uptake
data. J Cereb Blood Flow Metab, 1985.
[25] M. Qin, J. Kang, T. V. Burlin, C. Jiang, and C. B. Smith.
Postadolescent changes in regional cerebral protein synthe-
sis: an in vivo study in the FMR1 null mouse. J Neurosci,
25(20):5087–95, 2005.
[26] Hawkins RA. Estimation of local cerebral protein synthesis
rates with L-[1-11C]leucine and PET: methods, model, and
results in animals and humans. Cereb Blood Flow Metab,
1989.
[27] K. Schmidt. Which linear compartmental systems can be
analyzed by spectral analysis of PET output data summed
over all compartments? J Cereb Blood Flow Metab,
19(5):560–9, 1999.
[28] K. C. Schmidt, M. P. Cook, M. Qin, J. Kang, T. V. Burlin,
and C. B. Smith. Measurement of regional rates of cerebral
protein synthesis with L-[1-11C]leucine and PET with cor-
rection for recycling of tissue amino acids: I. kinetic mod-
eling approach. J Cereb Blood Flow Metab, 25(5):617–28,
2005.
168
[29] C. B. Smith and J. Kang. Cerebral protein synthesis in a
genetic mouse model of phenylketonuria. Proc Natl Acad
Sci U S A, 97(20):11014–9, 2000.
[30] C. B. Smith, K. C. Schmidt, M. Qin, T. V. Burlin, M. P.
Cook, J. Kang, R. C. Saunders, J. D. Bacher, R. E. Car-
son, M. A. Channing, W. C. Eckelman, P. Herscovitch,
P. Laverman, and B. K. Vuong. Measurement of regional
rates of cerebral protein synthesis with L-[1-11C]leucine and
pet with correction for recycling of tissue amino acids: II.
validation in rhesus monkeys. J Cereb Blood Flow Metab,
25(5):629–40, 2005.
[31] C.B. Smith. Measurament of local cerebral protein synthesis
in vivo: influence of recyling of amino acids derived from
protein degradation. Proc Natl Acad Sci USA, 85(23):9341–
5, December 1988.
[32] A.R. Studenov, D.E. Szalda, and Ding Y.S. Synthesis of
nocarrier-added C-11 labeled D- and l-enantiomers of pheny-
lalanine and tyrosine for comparative PET studies. Nucl
Med Biol, 2003.
[33] Y. Sun, G. E. Deibler, J. Jehle, J. Macedonia, I. Dumont,
T. Dang, and C. B. Smith. Rates of local cerebral protein
synthesis in the rat during normal postnatal development.
Am J Physiol, 268(2 Pt 2):R549–61, 1995.
[34] S. K. Sundaram, O. Muzik, D. C. Chugani, F. Mu, T. J.
Mangner, and H. T. Chugani. Quantification of protein
synthesis in the human brain using L-[1-11C]-leucine PET:
incorporation of factors for large neutral amino acids in
plasma and for amino acids recycled from tissue. J Nucl
Med, 47(11):1787–95, 2006.
169
[35] G. Tomasi, A. Bertoldo, and K. Schmidt. Voxel-based esti-
mation of kinetic model parameters of the L-[1-11C]leucine
PET method for determination of regional rates of cerebral
protein synthesis: Validation and comparison with region-
of-interest based methods. Submitted to Journal of Cerebral
Blood Flow Metabolism, 2009.
[36] F. Turkheimer, R. M. Moresco, G. Lucignani, L. Sokoloff,
F. Fazio, and K. Schmidt. The use of spectral analy-
sis to determine regional cerebral glucose utilization with
positron emission tomography and [18F]fluorodeoxyglucose:
theory, implementation, and optimization procedures. J
Cereb Blood Flow Metab, 14(3):406–22, 1994.
[37] F. Turkheimer, L. Sokoloff, A. Bertoldo, G. Lucignani,
M. Reivich, J. L. Jaggi, and K. Schmidt. Estimation of
component and parameter distributions in spectral analy-
sis. J Cereb Blood Flow Metab, 18(11):1211–22, 1998.
[38] J. Ventura, R. P. Liberman, M. F. Green, A. Shaner, and
J. Mintz. Training and quality assurance with the struc-
tured clinical interview for DSM-IV (SCID-I/P). Psychiatry
Res, 79(2):163–73, 1998.
[39] R. Widmann, M. Kocher, R. I. Ernestus, and K. A. Hoss-
mann. Biochemical and autoradiographical determination
of protein synthesis in experimental brain tumors of rats. J
Neurochem, 59(1):18–25, 1992.
[40] R. Widmann, T. Kuroiwa, P. Bonnekoh, and K. A. Hoss-
mann. [14C]leucine incorporation into brain proteins in ger-
bils after transient ischemia: relationship to selective vul-
nerability of hippocampus. J Neurochem, 56(3):789–96,
1991.
170
[41] K Wienhard. The ECAT HRRT: Performance and first
clinical application of the new high resolution research to-
mogrph. IEEE Trans Nucl Sci, pages 104–110, 2002.
[42] Y. Wu and R. E. Carson. Noise reduction in the simplified
reference tissue model for neuroreceptor functional imaging.




I thank my professor Alessandra Bertoldo for the pos-
sibility to write my thesis in an important research
center, such as the NIH. I thank Kathleen Schmidt for
the invaluable teaching that she provided me during all
my work. I thank the SNPM, in particular the chief
Carolyn Beebe Smith, PhD., Dr. Bishu, Aaron and
Ariel for the help and the patience that they had with
me and my English. I thank also the Bioengineer-
ing group of Padova, in particular Denis who taught
some interesting “secrets”of Matlab. Thank you to
everyone that has contributed to the realization of this
work.
173
